Improving Cancer Immunotherapy Treatment
Patent Information
- Application Number
- JP2024531432
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-29
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-15
Smart Images

Figure 2024542593000001_ABST
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Patent Application No. 63 / 283,697, filed November 29, 2021, the disclosure of which is incorporated by reference in its entirety.
[0002] The present invention relates to a cancer immunotherapy treatment.
[0003] Cancer is the second leading cause of death after heart disease (www.cdc.gov / nchs / fastats / leading-causes-of-death.htm), and research is abundant and ongoing to identify effective therapeutic agents to treat subjects with any cancer. As cancer types are diverse, it is not surprising that the pharmacology aimed at treating or eradicating cancer is equally diverse, including drug therapies such as chemotherapy, immunotherapy, radiation therapy, and nuclear therapy. Cancer immunotherapy shows great promise and is based on a wide variety of biological, drug, and cellular therapies, such as CAR-T cell immunotherapy. However, these treatments are suboptimal and associated with severe adverse events. Here, we describe the application of adsorbent technology to modulate immune responses as a first-line cancer immunotherapy, as a way to improve responses to other cancer therapies, and as a way to reduce adverse events such as cytokine release syndrome (CRS), neurotoxicity and CAR-T cell-associated encephalopathy, and tumor lysis syndrome (TLS). As with any medical treatment, complications and side effects arising from treatment can negatively impact a patient's quality of life, leave them debilitated and vulnerable to opportunistic infections, or even lead them to discontinue treatment altogether.
[0004] One example of a complication of cancer treatment is cytokine release syndrome (CRS). It occurs when activated white blood cells release cytokines, which further activate white blood cells and other cells capable of producing cytokines. This positive feedback loop can cause cytokine levels to continue to rise, eventually resulting in a cytokine storm, or cytokine release syndrome (CRS). The increased cytokine levels observed in CRS can cause undesirable symptoms in subjects, such as fever, muscle and joint pain, diarrhea, vomiting, cardiac and blood pressure changes, organ damage, organ failure, and death. In a similar phenomenon, subjects can develop immune-related adverse events (irAEs). Immune-related adverse events often include rash, diarrhea, autoimmune hepatitis, colitis, arthritis, pneumonia, and endocrine disorders. Initial activation of immune system cells is caused by the application of immunotherapies such as monoclonal antibody therapy, agonists or antagonists against cell surface receptors or proteins, bispecific T cell engagers, or adaptive T cell therapy involving T cells expressing chimeric antigen receptors (CAR-T cell therapy). In some cases, elevated cytokine levels may even directly interfere with cancer treatment itself.
[0005] CAR-T cell-associated encephalopathy syndrome (CRES) is a neurotoxicity observed in patients undergoing CAR-T therapy that may occur simultaneously with, during, or after CRS. Other terms associated with CRES include immune effector cell-associated neurotoxicity syndrome (ICANS) or chimeric antigen receptor T cell therapy-associated toxicity (CARTOX). Symptoms of severe forms of CRES, also associated with elevated cytokine concentrations, include seizures, incontinence, motor impairment, elevated intracranial pressure, psychiatric disorders, and death. In clinical trials, CRES often occurs after the onset of CRS. CRS and cytokine storm are associated with the disruption of endothelial tight junctions, capillary leak syndrome, and subsequent disruption of the blood-brain barrier, allowing activated CAR-T lymphocytes and other leukocytes to invade the normally protected central nervous system and cause inflammation. CRES that develops after CRS is generally more prolonged and severe than CRES that develops simultaneously with CRS.
[0006] Cachexia is a wasting syndrome characterized by significant weight loss. It is a severe end-stage complication in cancer patients and many other chronic diseases, including AIDS (acquired immune deficiency syndrome), chronic kidney disease, heart failure, and burn recovery. In addition to severe weight loss accompanied by muscle and fat wasting, cachexia often leads to significant debilitation and frailty, making patients less able to tolerate ongoing cancer treatment and more susceptible to life-threatening complications such as infection and sepsis. Without wishing to be bound by theory, it is believed that inflammation and elevated cytokine levels are at least partially responsible for the development and progression of cachexia. The weight loss and debilitation associated with cachexia are not improved by standard nutritional support in many cancer patients, often leading to complications and death.
[0007] Another deadly complication of cancer treatment is tumor lysis syndrome (TLS). When treatment causes large numbers of cancer or tumor cells to lyse and cellular components of the lysed tumor cells are deposited in the bloodstream, patients are at increased risk of TLS. Often associated with blood cancers such as leukemia, TLS is characterized by high blood levels of potassium, phosphorus, uric acid, and blood urea nitrogen and low blood levels of calcium, and symptoms include nausea, nephropathy, acute kidney failure, seizures, cardiac arrhythmias, and death.
[0008] Complications resulting from cancer and cancer treatment, such as CRS, CRES, TLS, cachexia, and other cancer-related diseases, side effects, syndromes, and symptoms, remain a major challenge in treating patients. New approaches are needed to eliminate or reduce the severity of cancer treatment complications and improve the effectiveness of cancer treatment.
[0009] In addition to reducing the severity and incidence of complications associated with cancer and cancer treatment, there is a need to improve the efficacy of cancer treatment and develop better cancer therapies. Cancer cells have evolved ingenious ways to evade recognition and destruction by the host's immune system and other defenses (immunosurveillance) and to reduce the immune response and the activity of a wide range of immune effector leukocytes (e.g., lymphocytes, granulocytes, and antigen-presenting cells such as dendritic cells and macrophages). For example, many cancers secrete or shed soluble or extracellular vesicle-associated checkpoint molecules from the cell membrane surface (e.g., cancer cells, leukocytes, platelets, and cells within the tumor microenvironment). These are ligands or receptors that cause immune suppression by one of a number of mechanisms, such as inhibiting the activation of leukocytes (e.g., cytotoxic T cells, NK natural killer cells), triggering inhibitory signaling pathways or immune checkpoints that reduce leukocyte activity or induce leukocyte apoptosis, or inhibiting leukocytes from recognizing and killing cancer cells. These ligands often target cell surface molecules or receptors on white blood cells that normally regulate immune cell function, such as CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1 (PD-1), T-cell immunoglobulin mucin 3 (TIM3), B- and T-lymphocyte attenuator (BTLA), natural killer cell receptor NKG2D (natural killer group 2, member D), and lymphocyte-activation gene-3 (LAG-3). Examples of these ligands include soluble or extracellular vesicle-associated PD-L1 and soluble or extracellular vesicle-associated PD-L2 ligands, which activate the PD-1 receptor on cytotoxic T cells, decreasing T-cell activity and preventing cell-mediated tumor killing.
[0010] Another example includes soluble NKG2D ligands such as MHC class I chain-related proteins A (sMICA) and B (sMICB) and HCMV UL-16 binding protein (sULBP2), which bind to NKG2D receptors on natural killer cells, induce internalization, and reduce the expression of NKG2D receptors on the cell surface, reducing the ability of these NK cells to kill tumor cells. Another example is soluble FAS ligand (sFasL), which induces apoptosis of lymphocytes. Another example is soluble CD40 ligand (sCD40L), which may promote the activity of immunosuppressive myeloid-derived suppressor cells and regulatory T cells, resulting in immunosuppression in cancer. Yet another example is soluble CTLA-4 (sCTLA-4), which is an alternatively spliced mRNA form of a membrane-bound isoform that can bind to CD80 / CD86, reduce T cell responses, and cause immunosuppression. High concentrations of these ligands have been observed to be associated with aggressive and refractory cancers in both animal studies and clinical trials. The use of checkpoint inhibitors (e.g., drugs, small molecules, biologics, monoclonal antibodies) that block PD-1 activation (e.g., pembrolizumab, nivolumab) or PD-L1 ligands (e.g., atezolizumab, avelumab, durvalumab) is a promising anticancer approach. Similarly, CTLA-4 inhibitors (e.g., ipilimumab) are also promising approaches. However, these checkpoint inhibitors only target one of many different mediators that may contribute to immune evasion by tumors, which may increase autoimmunity or cytokine release syndrome. A broader spectrum approach that can reduce many known and unknown substances in the blood that contribute to tumor growth and evasion may lead to more effective treatments.
[0011] Additionally, there is a need for methods to harmonize, optimize, or modulate a subject's immunological state before, during, or after administration of cancer immunotherapeutics, including CAR-T cell immunotherapy. For example, there is a wide variability in subjects' immune responses, spanning the full spectrum from immunosuppression to immune activation. This can affect responses to cancer immunotherapy and contribute to an increased risk of adverse events, such as cytokine release syndrome. Much of this heterogeneity is caused by a wide range of immune stimulatory and immunosuppressive substances in the bloodstream, including cytokines, chemokines, and soluble ligands, that affect immune system function. For example, pretreatment to normalize a subject's immune response prior to immunotherapy may result in fewer adverse events and more consistent results.
[0012] The present disclosure addresses these and other needs. Summary of the Invention
[0013] Provided herein is a method for treating a subject with a therapeutically effective amount of an adsorbent for treating dangerous complications of cancer therapy and immunotherapy (e.g., checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, oncolytic viruses, cytokines, and combinations thereof), such as cytokine release syndrome, cytokine storm, tumor lysis syndrome, and CAR-T cell-associated encephalopathy, wherein the treatment reduces dangerous concentrations of one or more of cytokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products. In one embodiment, the adsorbent treatment reduces neurotoxicity and CAR-T cell-associated encephalopathy by reducing the entry of CAR-T cells and other activated cells into the central nervous system, for example, by reducing damage from CRS or promoting repair of disrupted endothelial tight junctions that may cause capillary leakage of the blood-brain barrier. Also provided is a method for directly treating a subject's cancer with a therapeutically effective amount of an adsorbent. In one embodiment, the adsorbents can reduce inhibitors of the immune system, thereby restoring immune surveillance and restoring or enabling an immune response to attack and kill cancer cells. Such methods can also be combined with other cancer treatments or immunotherapies.
[0014] Methods are also provided for treating a subject with a therapeutically effective amount of an adsorbent to optimize, regulate, balance or modulate the immune system before, during or after cancer immunotherapy treatment, as a way to improve the strength, durability or predictability of the response to cancer immunotherapy or to reduce the risk of adverse events. In one embodiment, the adsorbent can be used to treat the blood to reduce excess levels of anti-inflammatory or pro-inflammatory mediators and balance the immune response.
[0015] Methods for treating or preventing natural inflammation-induced complications of cancer, such as cancer cachexia, are also provided.
[0016] The sorbents disclosed in the methods of the present disclosure can be, in some embodiments, porous biocompatible polymers, and in some embodiments, coated porous biocompatible polymers. In some embodiments, the porous biocompatible polymers can include dispersants or ion exchange polymers, and in some embodiments, the polymers can be hydrogels, cellulosics, or ion exchange polymers. The sorbents disclosed herein can have pore diameters between about 50 Å and about 40,000 Å, and in some embodiments of the present disclosure, the sorbents can include a heterogeneous population of polymers having pore diameters between about 50 Å and about 40,000 Å. In other embodiments of the present disclosure, the sorbents can include a heterogeneous population of polymers having pore diameters between about 50 Å and about 10,000 Å. In yet other embodiments of the present disclosure, the sorbents can include a heterogeneous population of polymers having pore diameters between about 50 Å and about 3000 Å.
[0017] In some embodiments of the present disclosure, the substance for which the adsorbent is therapeutically effective is a) a cytokine or chemokine, such as an interleukin, an interferon, a tumor growth factor, or a member of the tumor necrosis factor family; b) a soluble checkpoint molecule, the examples of which are shown in Table 1; or c) an extracellular vesicle associated with a checkpoint molecule, the examples of which are shown in Table 1. TIFF2024542593000002.tif80141TIFF2024542593000003.tif69141
[0018] Some embodiments of the methods described herein are used to treat a subject in need of immunotherapy and further include administering the immunotherapy. In some embodiments, the application of the immunotherapy is performed after the application of the adsorbent. The application of the adsorbent and the immunotherapy induces a coordinated immune response in the subject in some aspects of the present disclosure. [Brief description of the drawings]
[0019] [Figure 1]Benchtop evaluation data showing the mean removal of sPD-L1 from bovine whole blood using CytoSorb and control. Data represent the mean ± SD and each group was evaluated in triplicate (n=3). Cytosorb 60 and 120 indicate the volume of Cytosorb used (60mL and 120mL, respectively). Control 60 and 120 are control (placebo, no Cytosorb) groups evaluated at the same time as the treatment (Cytosorb) groups. [Diagram 2] Figure 2A shows the average remaining percentages of sCTLA-4, sTIM-3, sLAG-3, and sPD-L1 in bovine plasma in the control and cytosorb groups. Data represent the mean ± SD (n=3), *p<0.05. Figure 2B shows the average remaining percentages of sPD-L2, sPD-1, sICOS, and sVISTA in bovine plasma in the control and cytosorb groups. Data represent the mean ± SD (n=3), *p<0.05, n=2 for sPD-1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] The present invention generally relates to cancer treatment utilizing porous biocompatible polymeric adsorbents. In a first scenario, the adsorbents are used to treat cancer by removing factors that inhibit the immune response to cancer cells. In a second scenario, the adsorbents modulate the immune system before, during, or after treatment of a subject with a cancer treatment or immunotherapy. In a third scenario, the adsorbents reduce inflammation-induced cancer complications (such as cachexia). In a fourth scenario, the adsorbents improve the efficacy of a cancer treatment or immunotherapy.
[0021] If necessary, detailed embodiments of the present invention are disclosed herein. It should be understood that the disclosed embodiments are merely examples of the present invention, which may be embodied in various forms. Therefore, the specific structural and functional details disclosed herein should not be interpreted as limitations, but merely as a basis for teaching those skilled in the art how to use the present invention. The following specific examples can help to better understand the present invention. However, these are merely provided as guidance and are not intended to be limiting in any way.
[0022] The present invention may be more readily understood by reference to the following detailed description taken in conjunction with the accompanying figures and examples, which form a part of this disclosure. It is to be understood that the present invention is not limited to the specific materials, devices, methods, applications, conditions, or parameters described and / or illustrated herein, and that the terms used herein are for the purpose of describing specific embodiments by way of example, and are not intended to limit the invention as claimed. As used herein, the term "plurality" means one or more. When a range of values is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, it will be understood that the particular value forms another embodiment by use of the antecedent "about." All ranges are inclusive and combinable.
[0023] It is to be understood that certain features of the invention that are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any combination of components. Further, references to values recited in ranges include each and every value and combination of values within that range.
[0024] definition The following definitions are used herein: Unless otherwise specified, terms have the meanings commonly used in the art.
[0025] Throughout the description and claims of this specification, the words "comprise" and "contain" and variations thereof, such as "comprising" and "comprises," mean "including but not limited to" and are not intended to (and do not) exclude other ingredients.
[0026] The term "biocompatible" means that the adsorbent is capable of contacting physiological fluids, biological tissues, or organisms without causing unacceptable clinical changes while in contact with the physiological fluids, biological tissues, or organisms.
[0027] As used herein, the terms "treat", "treating" or "treatment" of any disease, condition, syndrome or disorder refer in one embodiment to ameliorating the disease, condition, syndrome or disorder (i.e., slowing or arresting or alleviating the onset of the disease or at least one of its clinical symptoms). In another embodiment, "treat", "treating" or "treatment" refers to alleviating or improving at least one physical parameter, including one that may not be discernible by the patient. In a further embodiment, "treat", "treating" or "treatment" refers to modulating the disease, condition, syndrome or disorder, either physically (e.g., stabilization of a discernible symptom), physiologically (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treat", "treating" or "treatment" refers to preventing or delaying the onset or onset or progression of the disease, condition, syndrome or disorder.
[0028] The term "hemocompatible" is defined as the condition in which a biocompatible material produces a clinically acceptable physiological change when in contact with whole blood or plasma.
[0029] As used herein, the term "physiologic fluids" refers to fluids originating from the body, including, but not limited to, nasopharyngeal, oral, esophageal, stomach, pancreatic, liver, pleura, pericardium, peritoneum, intestine, prostate, semen, vaginal secretions, tears, saliva, lung, bronchial secretions, mucus, bile, blood, lymph, plasma, serum, synovial fluid, urine, cerebrospinal fluid, interstitial fluid, tears, saliva, lung or bronchial secretions, mucus, bile, blood, lymph, plasma, serum, synovial fluid, cerebrospinal fluid, urine, interstitial fluid, intracellular fluid, and extracellular fluid (such as fluid exuded from burns, wounds, cancerous tumors, etc.).
[0030] As used herein, the term "sorbent" includes adsorbents and absorbents.
[0031] For purposes of this invention, the term "sorb" is defined as "taking up and binding by absorption and / or adsorption."
[0032] As used herein, the singular forms "a," "an," and "the" include the plural, and reference to a particular numerical value includes at least that particular value, unless the context clearly dictates otherwise. When a range of values is expressed, it includes, in another embodiment, from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it is understood that the particular value forms another embodiment. Additionally, when used in connection with a numerical range, cutoff value, or specific value, the term "about" is used to indicate that the stated value may vary by up to 10% from the stated value. Use of the antecedent "about" is understood to encompass the particular value stated. All ranges are inclusive and combinable.
[0033] As used herein, the phrase "therapeutically effective dose" refers to an amount of an adsorbent or other therapeutic agent administered that is effective to achieve a particular biological or therapeutic result, such as, but not limited to, the biological or therapeutic results disclosed, described, or exemplified herein. A therapeutically effective dose may vary depending on factors such as the disease state, age, sex, and weight of the individual, as well as the ability of the composition to elicit a desired response in the subject. Such results include, but are not limited to, the treatment of cancer, as determined by any means suitable in the art.
[0034] The term "subject" as used herein is intended to mean any animal, particularly a mammal, and any type of mammal can be treated using the disclosed method. Thus, the method is applicable to humans and non-human animals, but is preferably used in mice and humans, and most preferably in humans. "Subject" and "patient" are used interchangeably throughout this disclosure.
[0035] "Monomer residue" refers to the portion of a monomer that becomes incorporated into a polymer when the monomer is polymerized. For example, if Rx reacts with R'-y to form R-R', where x and y are liberated during the reaction, R and R' are monomer residues.
[0036] For purposes of this invention, the term "perfusion" is defined as passing a physiological fluid once through a device containing a porous polymeric adsorbent, or through a suitable extracorporeal circuit, to remove toxic molecules from the fluid.
[0037] "Hemoperfusion" is a special case of perfusion in which the physiological fluid is blood.
[0038] The term "dispersant" or "dispersing agent" is defined as a substance that exerts a stabilizing effect on an arrangement of finely divided immiscible liquid droplets suspended in a fluid medium.
[0039] The term "heparin mimicking polymer" refers to any polymer that has the same anticoagulant and / or antithrombotic properties as heparin. In some embodiments, the adsorbent can act as a heparin mimicking polymer by having functional groups on the adsorbent surface selected from SO3H, COOH, and -OH (or salts thereof). These functional groups can be attached to the adsorbent polymer by methods known to those of skill in the art. See, for example, Ran, et al. Macromol. Biosci. 2012, 12(1), 116-25. Suitable salts include -SO3 - M + , -COO - M + , -O - M + where M is Na or K.
[0040] The term "macroreticular synthesis" is defined as the polymerization of monomers into polymers in the presence of an inert precipitating agent, which forces the growing polymer molecules out of the monomer liquid at a certain molecular size defined by phase equilibrium, giving solid nano-sized microgel particles with spherical or nearly spherical symmetry, packed together with beads having physical pores with an open cell structure [U.S. Pat. No. 4,297,220, Meitzner and Oline, October 27, 1981; RL Albright, Reactive Polymers, 4, 155-174 (1986)].
[0041] The term "hypercrosslinked" describes polymers in which a single repeat unit has two or more connectivity. Hypercrosslinked polymers are prepared by crosslinking swollen or dissolved polymer chains with a large number of rigid crosslinking spacers, rather than by copolymerization of monomers. Crosslinkers include bis(chloromethyl) derivatives of aromatic hydrocarbons, methylal, monochlorodimethyl ether, and other bifunctional compounds that react with polymers in the presence of Friedel-Crafts catalysts [Tsyurupa, MP, ZK Blinnikova, NA Proskurina, AV Pastukhov, LA Pavlova, and VADavankov. "Hypercrosslinked Polystyrene: The First Nanoporous Polymeric Material." Nanotechnologies in Russia 4(2009):665-75.].
[0042] Use of the adsorbent of the present invention in cancer and its treatment Cancer treatment and immunotherapy are carried out by conventional techniques well known in the art.
[0043] In some embodiments, the biocompatible polymeric adsorbents act to remove undesirable compounds by sorption of these undesirable compounds within the pores of the adsorbent, thereby treating cancer.
[0044] PD-1 is a protein found on immune cells called T cells. PD-1 normally acts as an "off switch" that prevents T cells from attacking other cells in the body. PD-1 can bind to a protein found on normal cells (and cancer cells) called PD-L1. This interaction signals the T cell not to attack that cell. Certain cancer cells have high levels of PD-L1, allowing them to evade the immune system. Many types of cancer express PD-L1, including non-small cell lung cancer, natural killer / T-cell lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, multiple myeloma, oral squamous cell carcinoma, breast cancer, ovarian cancer, urothelial carcinoma, colon cancer, and malignant melanoma. High levels of PD-L1 often correlate with poor clinical outcomes.
[0045] Therapies that target either PD-1 or PD-L1 can block the proteins from adhering to each other and help prevent cancer cells from evading the immune system. The present disclosure provides a method for regulating cytokine concentrations in a subject, which is beneficial for people undergoing or preparing to undergo immunotherapy for the treatment of cancer. Modulation of cytokine concentrations is an important advance in cancer treatment, as some cytokines are known to inhibit immune responses to tumors. Thus, one embodiment of the present disclosure is a method for enhancing responsiveness to immunotherapy in a subject, comprising administering to the subject a therapeutically effective amount of an adsorbent for immunosuppressive cytokines. In certain embodiments, the method of the present invention targets PD-L1 by using an adsorbent that adsorbs PD-L1.
[0046] PD-L2 is a second ligand for PD-1 and can inhibit T cell-cell interactions.
[0047] A soluble form of PD-1, sPD-1, is associated with poor prognosis in certain cancers.
[0048] sMICA is a soluble ligand for the immune receptor natural killer receptor 2 (NKG2D). sMICB and sULBP2 are also soluble ligands for NKG2D.
[0049] The Fas receptor is a cell surface death receptor that can lead to programmed cell death. Fas ligand (FasL) is known to enable Fas to evade immune surveillance.
[0050] sCTLA-4 is a soluble form of cytotoxic T-lymphocyte-associated antigen-4 (sCTLA-4).
[0051] sCD40L is a soluble ligand that induces the release of specific inflammatory mediators.
[0052] Gal-9 is a soluble ligand of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3). sHMGB1 is another soluble ligand of TIM-3.
[0053] sHVEM is a soluble ligand for B and T lymphocyte attenuator (BTLA).
[0054] LIGHT is a ligand of the tumor necrosis factor superfamily and binds to HVEM.
[0055] VSIG-3 is a ligand for V-domain Ig inhibitor of T cell activation (VISTA).
[0056] FGL1 is a soluble ligand of lymphocyte activation gene 3 (LAG-3). MHC class II, Gal-3, and LSECtin are also soluble ligands of LAG-3.
[0057] sB7-H6 is a soluble ligand for the natural killer cell-activating receptor NKp30, and sBAG6 and Gal-3 are also soluble ligands for NKp30.
[0058] sB7-H4 (sVCTN1) and sB7-H3 are soluble immune checkpoint molecules.
[0059] sPVR (sCD155) is a soluble ligand of the T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), and sPVRL2 (sCD112), sNectin-3, and sNectin-4 are also soluble ligands of TIGIT.
[0060] sB7-1 is a soluble ligand for CTLA-4, and sB7-2 is also a soluble ligand for CTLA-4.
[0061] sB7H7 is a soluble ligand of the transmembrane immunoglobulin domain-containing receptor 2 (TMIGD2).
[0062] Adenosine is a soluble ligand for the adenosine A1 receptor (ADORA1). Adenosine is also a ligand for the adenosine A2a receptor (ADORA2a).
[0063] sCEACAM1 is a soluble form of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).
[0064] sCD-47 is a soluble ligand of signal regulatory protein α (SIRPα).
[0065] sCD200 is a soluble ligand for the CD200 receptor (CD200R).
[0066] Inducible T cell costimulator (ICOS) is a costimulator molecule of the CD28 superfamily expressed on activated T cells. It is thought to be particularly important for T helper cells. It plays an important role in controlling intercellular signaling, immune responses, and cell proliferation.
[0067] Checkpoint inhibitors are drugs that can block certain proteins made by immune system cells that, when present, can block T cells and other immune system cells from attacking cancer cells.
[0068] CAR T cell therapy improves the adhesion effect of the target T cells to cancer cells by modifying part of the T cells.
[0069] Monoclonal antibodies are a type of protein (usually made in a laboratory) that can bind to cancer cells and can be used to treat cancer.
[0070] Bispecific T cell engagers are a type of bispecific monoclonal antibody that are useful in cancer treatment by linking T cells to cancer cells.
[0071] A cancer vaccine is a vaccine that treats existing cancer or prevents cancer from developing.
[0072] Oncolytic viruses are viruses that preferentially lyse cancer cells but not normal cells.
[0073] Immunotherapy using the polymeric adsorbent of the present invention as intended herein refers to a therapeutic approach that induces an immune response against tumor or cancer cells expressing an antigen. When administered, immunotherapy activates white blood cells and releases both inflammatory and anti-inflammatory cytokines. Since some cytokines are immunosuppressive and can attenuate or even eliminate immune responses, another embodiment of the present disclosure is a method for enhancing immune responses in a subject, comprising administering a therapeutically effective amount of an adsorbent for cytokines to the subject.
[0074] The immune system of mammals, particularly humans, recognizes some antigens as foreign and responds with adaptive (antibody-mediated) and innate (cytokine-mediated) responses. Cancer and tumor cells originate from cells that are not foreign, but express antigens ("tumor antigens") that are recognized as foreign and trigger an immune response. Some cancer and tumor cells express certain immunosuppressive cytokines that reduce the ability of the immune system to recognize and respond appropriately to tumor antigens. For example, transforming growth factor beta (TGF-β) is known to blunt the immune system's ability to recognize tumor antigens, and its overexpression correlates with tumor progression. Application of an adsorbent that reduces the concentration and / or availability of TGF-β may enhance the recognition of tumor antigens by the immune system and the activation of effector cells that attack tumor or cancer cells expressing the tumor antigen. For these reasons, one embodiment contemplated herein is a method for enhancing an immune response in a subject, comprising administering to the subject a therapeutically effective amount of an adsorbent for cytokines.
[0075] The adsorbents can be used to directly treat cancer as described herein, or alternatively, the adsorbents can be utilized in conjunction with one or more therapeutic agents selected from anti-cancer agents, anti-cancer therapeutic agents, and immunotherapeutic agents.
[0076] Without being bound by theory, it is believed that the adsorbents described herein adsorb sufficient amounts of immunosuppressive cytokines such that the presence of tumor antigens is unmasked, causing the immune system to respond against tumor or cancer cells expressing the antigen.
[0077] For example, TGF-β and other cytokines have immunosuppressive properties that blunt the immune system's ability to attack cancer cells and tumors, but this ability can be restored by removing the problematic cytokines. Furthermore, in some cancer cases, traditional treatments may not be justified, desired, or contraindicated due to the patient's medical history, condition, or personal preferences. When the adsorbent is administered to the patient, the concentration of immunosuppressive cytokines is reduced, resulting in an enhanced immune response (compared to the response suppressed by the immunosuppressive cytokines) that can eliminate cancer cells.
[0078] As mentioned above, there are many examples of cytokine-mediated syndromes, disorders, or other diseases that may occur as a complication of immunotherapy.Therefore, one embodiment of the present disclosure is directed to a method for treating or preventing cytokine-mediated disease in a subject, comprising administering to the subject a therapeutically effective amount of an adsorbent for cytokine.In one aspect of this embodiment, the malignant disease is cachexia, CRS, CRES, TLS, or a combination thereof.In another embodiment, the malignant disease is systemic inflammation.
[0079] CRS and CRES are known to occur together in some subjects undergoing cancer treatment, and cachexia is expected to co-occur with any of the listed syndromes or other cancer-related side effects or complications, since cachexia is a prominent side effect of cancer treatment. Thus, one embodiment of the present disclosure is a method for treating or preventing CRS and CRES in a subject, comprising administering a therapeutically effective amount of an adsorbent for cytokines to a subject. Another embodiment of the present disclosure is a method for treating or preventing CRS and TLS, comprising administering a therapeutically effective amount of an adsorbent for cytokines to a subject. Another embodiment of the present disclosure is a method for treating or preventing CRS and cachexia, comprising administering a therapeutically effective amount of an adsorbent for cytokines to a subject. In yet another embodiment of the present disclosure, a method for treating or preventing CRES and TLS is provided, comprising administering a therapeutically effective amount of an adsorbent for cytokines to a subject. Another embodiment provides a method for treating or preventing CRES and cachexia, comprising administering a therapeutically effective amount of an adsorbent for cytokines to a subject. Another embodiment of the present disclosure provides a method for treating or preventing TLS and cachexia.
[0080] In yet another embodiment of the present invention, the adsorbent described herein is used as a pretreatment to immunomodulate patients who are going to undergo cancer immunotherapy, to homogenize the patient population, reduce the incidence of adverse outcomes (e.g., lower CRS, CRES, TLS, cachexia), and / or improve clinical outcomes (e.g., improved tumor antigen response rate, improved survival rate, reduced recurrence rate). Some patients are ineligible for immunotherapy treatment because T cells do not expand outside the body and are not successfully treated when reintroduced into the patient's body. The present method overcomes this problem, allowing more patients to receive treatment.
[0081] Another embodiment of the invention provides for administering a therapeutically effective amount of an adsorbent to a subject to reduce the concentration of a cytokine, where the reduction in the concentration of the cytokine conditions the subject for subsequent administration of a chimeric antigen receptor T cell therapy (CAR-T). Conditioning the subject can increase the probability that a subsequent immunotherapy, such as CAR-T, will be effective. Conditioning the subject can also be used to match groups of subjects so that subsequent treatments for the group are administered at approximately the same time. Matching subjects in this manner is ideal in research settings, but also in settings that are not equipped to administer expensive cancer treatments without sufficient lead time. For example, clinics in underserved or underserved locations may need to purchase multiple therapeutics to take advantage of bundled payments, or mobile clinics may need to administer treatments at intervals only at specific locations. Matching patients in such situations allows for efficient distribution of treatments, resulting in better treatment outcomes.
[0082] The present invention also relates to the treatment of cancer cachexia (also called cancer anorexic cachexia). Although cachexia is a common phenomenon in cancer and is sometimes a prominent indicator of the disease state, much of the interest and attention has been focused on the treatment of cancer rather than this complication. However, the nutritional deprivation characteristic of cachexia leaves many patients in a weakened state and unable to undergo advanced treatment, and for those whose cancer is refractory, palliative care is the last resort. Some embodiments of the present disclosure are methods for treating or preventing cachexia in a subject, comprising administering a therapeutically effective amount of an adsorbent for cytokines. As with other methods presented herein, the adsorbent can be administered before, during, or after the administration of anti-cancer therapy. By reducing the concentration of cytokines, cachexia can be prevented, eliminated, or symptoms can be reduced to a level where the patient can receive nutrition and better combat the underlying disease.
[0083] One aspect of the method disclosed herein for treating or preventing cytokine-mediated disease is the reduction of cytokine concentration. In some aspects of the disclosed embodiment, the reduction of the concentration of a single class or specific cytokine may be 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. A 100% reduction in cytokine concentration refers to a situation where the cytokine is not detected by any method used to detect the cytokine concentration in a subject.
[0084] The cytokines that are bound and effectively neutralized can be a single type of cytokine, a specific family of cytokines, a panel of cytokines, or even a random set of cytokines. The cytokines that are adsorbed using the methods and adsorbents described herein may have immunosuppressive, pro-inflammatory, or cancer-promoting properties. Examples of cytokines contemplated in this disclosure are interleukins (IL), members of the tumor necrosis family (TNF), interferons (IFN), and transforming growth factors (TGF). In some embodiments, the cytokines of interest are IL-2, IL-4, IL-6, IL-10, and IL-12. In some embodiments, the cytokines of interest include IFN-γ. In some embodiments, the cytokines of interest include TGF-β.
[0085] Another embodiment of the present invention provides a method for treating or preventing tumor lysis syndrome in a subject, comprising administering to the subject a therapeutically effective amount of an adsorbent for cytokines. TLS occurs when a large number of tumor cells are lysed by the treatment, thereby releasing the intracellular contents of the lysed cells. Not only are the intracellular contents released into the extracellular environment or bloodstream, but cytokines are also released. A sudden increase in cytokines can cause a systemic inflammatory response that can lead to organ failure and death. Since an adsorbent effective for cytokines can reduce the amount of cytokines, the described method can reduce the systemic inflammation associated with TLS by adsorbing the released cytokines.
[0086] Additionally, the administered therapeutically effective amount of the adsorbent may also adsorb cellular debris. As used herein, "cellular debris" refers to organic waste left behind after cells die, and the immune system is often involved in removing the debris. As in TLS, the amount of cellular debris released from a dying tumor may be sufficient to adversely affect the health of the subject. By adsorbing at least a portion of the cellular debris, the debris may be removed more efficiently than relying solely on the immune system. Such applications of the present invention may prove useful in immunocompromised patients whose immune systems are unable to effectively remove the debris.
[0087] Furthermore, the present invention can be used as a first-line treatment for cancer by removing soluble or extracellular vesicle-associated inhibitors of immune response. Often, these soluble inhibitors are classified as immune system checkpoint molecules. Thus, one embodiment of the present disclosure is a method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an adsorbent for immune system checkpoint molecules. Checkpoint molecules include, but are not limited to, programmed cell death protein 1, also known as PD-1, its ligands PD-L1 and PD-L2, and CTLA-4. For example, the adsorbent can remove PD-1 from the patient's body fluids, resulting in an effective immune response against cancer or tumor cells.
[0088] In addition to directly binding immune system checkpoint molecules, the adsorbents can be administered in conjunction with checkpoint inhibitors, which may be desirable when checkpoint inhibitors are toxic at high levels or when normal levels are toxic in some patients. Furthermore, whereas checkpoint inhibitors tend to be specific for certain checkpoint molecules, the adsorbents can adsorb any checkpoint molecule, especially those that are present in abnormally high concentrations.
[0089] Some embodiments of the methods described herein include treating blood or other bodily fluids with at least one of the disclosed porous biocompatible polymers. For example, blood from a patient can be treated outside the patient in a manner similar to dialysis. After the blood is removed from the patient, it is contacted with the disclosed porous biocompatible polymer before being returned to the patient. In some embodiments, the blood is taken from an appropriate artery, contacted with an adsorbent, and then returned to the patient through an appropriate vein. Methods for establishing a circuit to remove blood and return it to the patient are well known to those skilled in the art. In some aspects, the porous biocompatible polymer adsorbs circulating cytokines and other biomolecules that may inhibit cancer therapy, effectively removing them from the circulating blood. Thus, when the blood is returned to the patient, the concentration of the inhibiting cytokines or biomolecules is reduced, making them less likely to suppress, counteract, or otherwise inhibit immunotherapy.
[0090] In some embodiments of the present disclosure, the adsorbents are administered as adjuvant therapy to reduce the recurrence rate of cancer in patients, for example, after surgical removal of a tumor, to reduce the concentration of immunosuppressive cytokines or other cancer-promoting factors, allowing the immune system to monitor circulating cancer cells or early tumor development.
[0091] In some embodiments, the adsorbent is contained in a cartridge adapted for blood to flow into the cartridge and out of the cartridge and returned to the patient. Although a cartridge is typically utilized, other containers that allow blood to contact the adsorbent and then be returned to the patient are also utilized. One embodiment of the present disclosure relates to a kit that includes a cartridge containing an adsorbent for use in cancer immunotherapy treatment. The kit includes any of the polymers described herein. In some aspects, the kit includes instructions for use of the cartridge, and in some aspects, the instructions are included on a label affixed to the cartridge.
[0092] Alternatively, the adsorbent can be administered directly to the patient. For example, a therapeutically effective amount of the adsorbent can be administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, through a tube, or rectally. In some embodiments, the adsorbent can be administered directly to the tumor or tissue surrounding the tumor, resulting in less systemic effects, which is particularly beneficial when anti-cancer therapy is also administered intratumorally.
[0093] In some embodiments of the currently described method, the adsorbent is administered orally. This is a particularly effective means of administering the adsorbent systemically, and is particularly beneficial for patients experiencing CRS, CRES, TLS, or cachexia. Oral administration does not require invasive or lengthy procedures, which tend to be expensive. Furthermore, oral administration can be administered relatively easily and frequently (e.g., daily) compared to other means of administering therapeutic agents.
[0094] Adsorbents of the present disclosure suitable for use in the treatment of cancer or any of the other methods / applications described herein are biocompatible polymeric adsorbents having the following characteristics: pore diameters ranging between about 50 Å and about 3000 Å, alternatively about 50 Å and about 10,000 Å, alternatively about 50 Å and about 40,000 Å, alternatively about 50 Å and about 2000 Å, alternatively about 100 Å and about 1500 Å, alternatively about 1500 Å and about 6000 Å, alternatively about 1500 Å and about 15,000 Å, alternatively about 5000 Å and about 20,000 Å, alternatively about 4000 Å and about 40,000 Å; A pore volume between about 0.5 cc / g and about 3.0 cc / g of dry polymer, alternatively a pore volume between about 0.5 cc / g and about 4.0 cc / g of dry polymer, alternatively a pore volume between about 0.5 cc / g and about 5.0 cc / g of dry polymer.
[0095] In certain embodiments, the adsorbent comprises a pore structure such that the total pore volume for pore diameters in the range of 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g of dry adsorbent, and the ratio of the pore volume (pore diameter) from 50 Å to 40,000 Å to the pore volume (pore diameter) from 1,000 Å to 10,000 Å of the adsorbent is less than 2:1.
[0096] When used to treat cancer or in the related methods discussed herein, it is contemplated that the adsorbent is placed in proximity to the cancer. In certain embodiments, the adsorbent is placed within the tumor. It is also contemplated that the adsorbent treats cancer by selectively adsorbing proteins secreted by the cancer that affect the immune system.
[0097] Various non-limiting scenarios illustrate the treatment of the present invention: Scenario 1. An adsorbent used to treat cancer by removing factors that inhibit the immune response to cancer cells. Scenario 2. The adsorbent modulates the immune system before, during, or after treatment of a subject with cancer therapy or immunotherapy. Scenario 3. The adsorbent reduces inflammatory complications of cancer (e.g., cachexia). Scenario 4. Adsorbents improve the efficacy of cancer treatment or immunotherapy.
[0098] Certain embodiments of the present invention are directed to methods of treating cancer in a subject in need thereof using the adsorbents of the present disclosure, which methods (a) reduce the concentration of one or more of cytokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products relative to untreated subjects, (b) reduce the entry of CAR-T cells and other activated cells into the central nervous system relative to untreated subjects, (c) reduce inhibition of the immune system, and / or (d) reduce damage from cytokine release syndrome (CRS) relative to untreated subjects.
[0099] In one embodiment of the invention, a method of treating cancer includes administering to a subject a porous biocompatible polymeric adsorbent, the polymeric adsorbent having a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer, the administering step contacting the adsorbent with a physiological fluid of the subject. The adsorbent is administered extracorporeally, intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, tube-fed, or rectally. The physiological fluid is blood.
[0100] In another embodiment of the invention, a method of treating cancer comprises administering to a subject a porous biocompatible polymeric adsorbent, the polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer, the administering step contacting the adsorbent with a physiological fluid of the subject. The adsorbent is administered extracorporeally, intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, tube-fed, or rectally. The physiological fluid is blood.
[0101] In another embodiment of the invention, a method of treating cancer comprises administering to a subject a porous biocompatible polymeric adsorbent, the polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer, the administering step contacting the adsorbent with a physiological fluid of the subject. The adsorbent is administered extracorporeally, intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, tube-fed, or rectally. The physiological fluid is blood.
[0102] Another embodiment of the method of treating cancer comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer. In that embodiment, the adsorbent is extracorporeal. The physiological fluid is blood.
[0103] Another embodiment of the method of treating cancer comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer. In that embodiment, the adsorbent is extracorporeal. The physiological fluid is blood.
[0104] Another embodiment of the method of treating cancer comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer. In that embodiment, the adsorbent is extracorporeal. The physiological fluid is blood.
[0105] Another embodiment of a method of treating cancer includes providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging from about 50 Å to about 3000 Å and a pore volume between about 0.5 cc / g to about 3.0 cc / g dry polymer.
[0106] Another embodiment of a method of treating cancer includes providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging from about 50 Å to about 10,000 Å and a pore volume between about 0.5 cc / g to about 4.0 cc / g dry polymer.
[0107] Another embodiment of a method of treating cancer includes providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging from about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc / g to about 5.0 cc / g dry polymer.
[0108] In certain embodiments of the method of treating cancer, the adsorbent is used in combination with an anti-cancer drug, anti-cancer therapeutic agent, and / or immunotherapeutic agent. The adsorbent is administered prior to or simultaneously with the anti-cancer drug, anti-cancer therapeutic agent, and / or immunotherapeutic agent. The anti-cancer drug, anti-cancer therapeutic agent, and / or immunotherapeutic agent is one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
[0109] When used in a method for treating cancer, the subject's body fluid is depleted of one or more of a) cytokines or chemokines, b) soluble checkpoint molecules, and c) extracellular vesicles associated with checkpoint molecules. The soluble or extracellular vesicle-associated checkpoint molecules are one or more of the examples found in Table 1. The chemokines include one or more members of the interleukin, interferon, tumor growth factor, or tumor necrosis factor family. In certain embodiments, the soluble ligand is PD-L1.
[0110] Another embodiment of the present invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g of dry polymer for treating cancer. Another embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g of dry polymer for use in the manufacture of a medicament for treating cancer.
[0111] Another embodiment of the invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer for treating cancer. Another embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer for use in the manufacture of a medicament for treating cancer.
[0112] Another embodiment of the invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g of dry polymer for treating cancer. Another embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g of dry polymer for use in the manufacture of a medicament for treating cancer.
[0113] Another embodiment of the invention is a method of reducing inflammation-related complications of (a) cancer, or (b) cancer treatment or immunotherapy in a subject in need thereof using the adsorbent of the present disclosure. In one embodiment, the method reduces inflammation-related complications of cancer. In another embodiment, the method reduces inflammation associated with complications of cancer treatment. In another embodiment, the method reduces inflammation associated with complications of immunotherapy.
[0114] In one embodiment, a method of reducing inflammation-related complications of (a) cancer, or (b) cancer treatment or immunotherapy in a subject in need thereof comprises administering to the subject a porous biocompatible polymeric adsorbent, the polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer, the administering step contacting the adsorbent with a physiological fluid of the subject. The adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. The physiological fluid is blood.
[0115] In another embodiment, a method of reducing inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy in a subject in need thereof comprises administering to the subject a porous biocompatible polymeric adsorbent, the polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer, the administering step contacting the adsorbent with a physiological fluid of the subject. The adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. The physiological fluid is blood.
[0116] In another embodiment, a method of reducing inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy in a subject in need thereof comprises administering to the subject a porous biocompatible polymeric adsorbent, the polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer, the administering step contacting the adsorbent with a physiological fluid of the subject. The adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. The physiological fluid is blood.
[0117] In another embodiment, a method of reducing inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy in a subject in need thereof, comprises contacting a physiological fluid of said subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer, said physiological fluid being blood.
[0118] In another embodiment, a method of reducing inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy in a subject in need thereof, comprises contacting a physiological fluid of said subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer, said physiological fluid being blood.
[0119] In another embodiment, a method of reducing inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy in a subject in need thereof, comprises contacting a physiological fluid of said subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer, said physiological fluid being blood.
[0120] In an alternative embodiment, a method of reducing (a) cancer, or (b) inflammation-related complications of cancer therapy or immunotherapy in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer.
[0121] In an alternative embodiment, a method of reducing (a) cancer, or (b) inflammation-related complications of cancer therapy or immunotherapy in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer.
[0122] In an alternative embodiment, a method of reducing (a) cancer, or (b) inflammation-related complications of cancer therapy or immunotherapy in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter in the range of about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc / g to about 5.0 cc / g dry polymer.
[0123] Another embodiment of the present invention is a porous biocompatible polymeric adsorbent comprising a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g of dry polymer for use in the manufacture of a medicament for the reduction of inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g of dry polymer for use in the manufacture of a medicament for the reduction of inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy.
[0124] Another embodiment of the present invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g of dry polymer for use in the manufacture of a medicament for the reduction of inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g of dry polymer for use in the manufacture of a medicament for the reduction of inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy.
[0125] Another embodiment of the present invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g of dry polymer for use in the manufacture of a medicament for the reduction of inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g of dry polymer for use in the manufacture of a medicament for the reduction of inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy.
[0126] Another embodiment of the present invention is directed to a method of improving immune function in a subject in need thereof before, during, or after treatment with an anti-cancer agent, anti-cancer therapeutic agent, and / or immunotherapeutic agent using the adsorbents of the present disclosure. The subject has cancer. In one embodiment, the method improves immune function of the subject before treatment with an anti-cancer agent, anti-cancer therapeutic agent, and / or immunotherapeutic agent. In another embodiment, the method improves immune function of the subject after treatment with an anti-cancer agent, anti-cancer therapeutic agent, and / or immunotherapeutic agent. In yet another embodiment, the method improves immune function of the subject during treatment with an anti-cancer agent, anti-cancer therapeutic agent, and / or immunotherapeutic agent. The anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
[0127] In one embodiment, a method of improving immune function in a subject in need thereof comprises administering to the subject a porous biocompatible sorbent, the polymeric sorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer, the administering step contacting the sorbent with a physiological fluid, such as blood, of the subject. The sorbent is administered extracorporeally, intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0128] In another embodiment, a method of improving immune function in a subject in need thereof comprises administering to the subject a porous biocompatible sorbent, the polymeric sorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer, the administering step contacting the sorbent with a physiological fluid, such as blood, of the subject. The sorbent is administered extracorporeally, intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0129] In another embodiment, a method of improving immune function in a subject in need thereof comprises administering to the subject a porous biocompatible sorbent, the polymeric sorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer, the administering step contacting the sorbent with a physiological fluid, such as blood, of the subject. The sorbent is administered extracorporeally, intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0130] In one embodiment, a method of improving immune function in a subject in need thereof comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging from about 50 Å to about 3000 Å and a pore volume between about 0.5 cc / g to about 3.0 cc / g dry polymer. The contacting step comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. Alternatively, the adsorbent is extracorporeal. In a particular embodiment, the physiological fluid is blood.
[0131] In another embodiment, a method of improving immune function in a subject in need thereof comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer. The contacting comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. Alternatively, the adsorbent is extracorporeal. In a particular embodiment, the physiological fluid is blood.
[0132] In another embodiment, a method of improving immune function in a subject in need thereof comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer. The contacting comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. Alternatively, the adsorbent is extracorporeal. In a particular embodiment, the physiological fluid is blood.
[0133] In yet another embodiment, a method of improving immune function in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer.
[0134] In another embodiment, a method of improving immune function in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer.
[0135] In another embodiment, a method of improving immune function in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0136] Another embodiment of the invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer for use in the manufacture of a medicament for improving immune function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer for use in the manufacture of a medicament for improving immune function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent.
[0137] Another embodiment of the invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer for use in the manufacture of a medicament for improving immune function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer for use in the manufacture of a medicament for improving immune function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent.
[0138] Another embodiment of the invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer for use in the manufacture of a medicament for improving immune function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer for use in the manufacture of a medicament for improving immune function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent.
[0139] An alternative embodiment of the present invention is directed to a method of improving the efficacy of cancer treatment or immunotherapy in a subject in need thereof using the adsorbent of the present disclosure. The method improves the efficacy of cancer treatment. Alternatively, improves the efficacy of immunotherapy. In certain embodiments, the cancer treatment or immunotherapy comprises one or more of the following administrations: radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
[0140] In one embodiment, a method of improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof comprises administering to the subject a porous biocompatible sorbent, the polymeric sorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer, the administering step contacting the sorbent with a physiological fluid of the subject. The administration is extracorporeal, intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, topical, oral, nasal, via a feeding tube, or rectally. The physiological fluid is blood.
[0141] In another embodiment, a method of improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof comprises administering to the subject a porous biocompatible sorbent, the polymeric sorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer, the administering step contacting the sorbent with a physiological fluid of the subject. The administration is extracorporeal, intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, topical, oral, nasal, via a feeding tube, or rectally. The physiological fluid is blood.
[0142] In another embodiment, a method of improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof comprises administering to the subject a porous biocompatible sorbent, the polymeric sorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer, the administering step contacting the sorbent with a physiological fluid of the subject. The administration is extracorporeal, intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, topical, oral, nasal, via a feeding tube, or rectally. The physiological fluid is blood.
[0143] In another embodiment, a method of improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer. The adsorbent is extracorporeal. Alternatively, the contacting comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. The physiological fluid is blood.
[0144] In another embodiment, a method of improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer. The adsorbent is extracorporeal. Alternatively, the contacting comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. The physiological fluid is blood.
[0145] In another embodiment, a method of improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof comprises contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer. The adsorbent is extracorporeal. Alternatively, the contacting comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally. The physiological fluid is blood.
[0146] In yet another embodiment, a method of improving the effectiveness of cancer therapy or immunotherapy in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer.
[0147] In another embodiment, a method of improving the effectiveness of cancer therapy or immunotherapy in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer.
[0148] In another embodiment, a method of improving the effectiveness of cancer therapy or immunotherapy in a subject in need thereof comprises providing to the subject a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0149] Yet another embodiment of the present invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer for use in improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer for use in the manufacture of a medicament for improving the efficacy of cancer therapy or immunotherapy.
[0150] Yet another embodiment of the present invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer for use in improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer for use in the manufacture of a medicament for improving the efficacy of cancer therapy or immunotherapy.
[0151] Yet another embodiment of the present invention is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g of dry polymer for use in the manufacture of a medicament for improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof. An alternative embodiment is a porous biocompatible polymeric adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g of dry polymer for use in the manufacture of a medicament for improving the efficacy of cancer therapy or immunotherapy.
[0152] In certain embodiments of the methods or uses, said adsorbent adsorbs PD-L1.
[0153] In certain embodiments of the methods or uses, said adsorbent adsorbs PD-L1-associated extracellular vesicles.
[0154] In any of these methods or uses, the adsorbent comprises a pore structure such that the total pore volume for pore diameters in the range of 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g of dry adsorbent, and the ratio of the pore volume (pore diameters) of the adsorbent from 50 Å to 40,000 Å to the pore volume (pore diameters) of the adsorbent from 1,000 Å to 10,000 Å is less than 2:1.
[0155] As used herein, when the methods refer to administering, the administering step includes providing the adsorbent with access to a physiological fluid, for example, when the fluid is blood, this can be accomplished by placing the adsorbent in or connecting it to a blood vessel.
[0156] Adsorbent The present invention also provides a porous polymeric adsorbent suitable for use in the cancer treatment and related methods described herein. The porous polymeric adsorbent is configured to adsorb cytokines, interleukins, chemokines, tumor necrosis factors, interferons, lymphokines, and other proteins involved in immune dissociation from a patient's physiological fluids. In certain embodiments, the adsorbent is configured to remove such proteins from the patient's blood.
[0157] The porous polymeric adsorbent is also configured to adsorb ligands and other proteins involved in immunosuppression from the physiological fluids of a patient, hi certain embodiments, the adsorbent is configured to remove such proteins from the blood of a patient.
[0158] The porous polymeric adsorbent is also configured to adsorb extracellular vesicles associated with cytokines, interleukins, chemokines, tumor necrosis factors, interferons, lymphokines, ligands, and other proteins involved in immunoparalysis or immunosuppression from the physiological fluids of the patient, hi certain embodiments, the adsorbent is configured to remove such vesicles from the blood of the patient.
[0159] The polymer can be incorporated into a pharmaceutical composition that includes the sorbent and a pharma- ceutically acceptable excipient or adjuvant. The polymer can be provided as a slurry, suspension, or wettable dry powder or other dry particles. In some methods, the sorbent is provided as a slurry or suspension packaged for oral administration, either in single or multi-dose packages. In other methods, the sorbent is provided as a slurry or suspension, either in single or multi-dose packages for enema or feeding tube administration, or a combination thereof.
[0160] The polymers can also be supplied as dry powders or other dry particulates that can be wetted externally or internally in the digestive tract, including the stomach or intestinal environment, with or without the addition of a wetting agent such as ethyl alcohol or isopropyl alcohol, hi yet other embodiments, the polymers are supplied as tablets, dry powders, other dry particulates, capsules, or suppositories packaged in bottles or blister packs for administration.
[0161] In some methods, the polymers are not metabolized by mammals, including humans, and when administered to a subject, are ultimately excreted from the subject as waste products, for example, the adsorbent bound to the target biomolecule and the unbound adsorbent are ultimately processed by the kidneys and excreted from the subject's body in the urine.
[0162] Without wishing to be bound by theory, it is believed that the treatment utilizes the adsorption capabilities of biocompatible polymers (also called adsorbents). "Biocompatible" refers to a polymer that can contact living tissue or organisms without causing harm while the polymer is in contact with the tissue or organism. In some embodiments, it is intended that the polymer is tolerated by the intestine and digestive tract of the organism. The polymers of the present invention are preferably non-toxic. In some aspects of the currently described methods, administration of the adsorbent can be performed before, simultaneously with, or after the application of immunotherapy or other cancer therapy.
[0163] In some embodiments, the polymer has a pore structure such that the total pore volume for pore diameters ranging between 50 Å and 3000 Å is greater than 0.5 cc / g to 3.0 cc / g, and the ratio of the pore volume (pore diameter) of the polymer from 50 Å to 3,000 Å to the pore volume (pore diameter) of the polymer from 500 Å to 3,000 Å is less than 200:1, and the ratio of the pore volume of the polymer from 50 Å to 3,000 Å to the pore volume of the polymer from 1,000 Å to 3,000 Å is greater than 20:1. The ratios can alternatively be defined in terms of pore surface area (such as the ratio of the pore surface area of the polymer from 50 Å to 3,000 Å to the pore surface area of the polymer from 50 Å to 3,000 Å), and are therefore alternative ways of defining the same pore structure.
[0164] In some embodiments, the polymer is a coated polymer comprising at least one crosslinker and at least one dispersant. In some embodiments, the polymer comprises at least one crosslinker, and in some embodiments, the polymer comprises at least one dispersant. Suitable dispersants include hydroxyethyl cellulose, hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylaminoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), poly(N-vinylpyrrolidinone), salts of poly(methacrylic acid), and salts of poly(acrylic acid), and mixtures thereof.
[0165] In some embodiments, the sorbent comprises at least one crosslinker, at least one monomer, at least one dispersant, and at least one porogen. Porogens that may be used in the present invention include benzyl alcohol, cyclohexane, cyclohexanol, cyclohexanol / toluene mixture, cyclohexanone, decane, decane / toluene mixture, di-2-ethylhexyl phosphoric acid, di-2-ethylhexyl phthalate, 2-ethyl-1-hexanoic acid, 2-ethyl-1-hexanol, 2-ethyl-1-hexanol / n-heptane mixture, 2-ethyl-1-hexanol / toluene mixture, isoamyl alcohol, n-heptane, n-heptane / ethyl acetate, n-heptane / isoamyl acetate, n-heptane / tetralin mixture, n-heptane / toluene mixture, n-hexane / toluene mixture, pentanol, , poly(styrene-co-methyl methacrylate) / dibutyl phthalate, polystyrene / 2-ethyl-1-hexanol mixtures, polystyrene / dibutyl phthalate, polystyrene / n-hexane mixtures, polystyrene / toluene mixtures, toluene, tri-n-butyl phosphate, 1,2,3-trichloropropane / 2-ethyl-1-hexanol mixtures, 2,2,4-trimethylpentane (isooctane), trimethylpentane / toluene mixtures, poly(propylene glycol) / toluene mixtures, poly(propylene glycol) / cyclohexanol mixtures, and poly(propylene glycol) / 2-ethyl-1-hexanol mixtures.
[0166] In certain embodiments, the dispersing agent comprises one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylaminoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), poly(N-vinylpyrrolidinone), a salt of poly(methacrylic acid), or a salt of poly(acrylic acid).
[0167] Suitable crosslinking agents include divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane, trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, and mixtures thereof. In some embodiments, the polymer is formed simultaneously with the formation of the coating so that the dispersant is chemically bonded to the surface of the polymer.
[0168] In some embodiments, the polymer is selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyl toluene, vinyl naphthalene, vinyl benzyl alcohol, vinyl formamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinyl naphthalene, trivinyl cyclohexane, divinyl sulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane triacrylate, trimethylolpropane trimeth ... The copolymer is derived from one or more monomers selected from divinylpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide, and mixtures thereof.
[0169] In some embodiments, the polymer is an ion exchange polymer. Such polymers include cross-linked polystyrene containing divinylbenzene residues. The polymer is typically a porous bead, and such polymers include acidic or basic functional groups. Suitable functional groups include sulfonic acid groups, amine groups, carboxylic acid groups, and salts thereof.
[0170] In some other embodiments of the present disclosure, the polymer is a cellulosic polymer. Suitable polymers include cross-linked dextran gels, such as Sephadex®.
[0171] The polymer according to some embodiments of the present disclosure is a porous, highly crosslinked styrene or divinylbenzene copolymer. In some embodiments, the polymer is a macroporous or mesoporous styrene-divinylbenzene-ethylstyrene copolymer that has undergone partial chloromethylation to a chlorine content of up to 7% by molecular weight. In other embodiments, the polymer is a hypercrosslinked polystyrene prepared from a crosslinked styrene copolymer by extensive chloromethylation followed by post-crosslinking in the swollen state with a Friedel-Crafts catalysis treatment. In yet other embodiments, the polymer is a highly crosslinked polystyrene prepared from a crosslinked styrene copolymer by extensive additional post-crosslinking in the swollen state with a bifunctional crosslinker selected from the group including monochlorodimethyl ether and p-xylylene dichloride.
[0172] In some embodiments, polymers useful in the practice of the present invention are hydrophilic self-wetting polymers that can be administered as dry powders that contain hydrophilic functional groups such as amine, hydroxyl, sulfonate, and carboxyl groups.
[0173] In some embodiments, the polymers useful in the present invention are macroporous polymers prepared from polymerizable monomers of styrene, divinylbenzene, ethylvinylbenzene, and acrylate and methacrylate monomers such as those listed by the following manufacturers: Rohm and Haas Company (now part of Dow Chemical Company): (i) macroporous polymer adsorbents, such as Amberlite™ XAD-1, Amberlite™ XAD-2, Amberlite™ XAD-4, Amberlite™ XAD-7, Amberlite™ XAD-7HP, Amberlite™ XAD-8, Amberlite™ XAD-16, Amberlite™ XAD-16HP, Amberlite™ XAD-18, Amberlite™ XAD-200, Amberlite™ XAD-300, Amberlite™ XAD-400, Amberlite™ XAD-500, Amberlite™ XAD-600, Amberlite™ XAD-700, Amberlite™ XAD-800, Amberlite™ XAD-900, Amberlite™ XAD-1000, Amberlite™ XAD-1100, Amberlite™ XAD-1200, Amberlite™ XAD-1300, Amberlite™ XAD-1400, Amberlite™ XAD-1500, Amberlite™ XAD-1600, Amberlite™ XAD-1700, Amberlite™ XAD-1800, Amberlite™ XAD-1900, Amberlite™ XAD-2000, Amberlite™ XAD-2000, Amberlite™ XAD-2000, Amberlite™ XAD-2000, Amberlite™ XAD-2000, Amberlite™ XAD-3 ... Chromatography grade adsorbents such as Amberlite™ AD-1180, Amberlite™ XAD-2000, Amberlite™ XAD-2005, Amberlite™ XAD-2010, Amberlite™ XAD-761, and Amberlite™ XE-305, as well as Amberchrom™ CG71,s,m,c, Amberchrom™ CG161,s,m,c, Amberchrom™ CG300,s,m,c, and Amberchrom™ CG1000,s,m,c. Dow Chemical Company: Dowex® Optipore™ L-493, Dowex® Optipore™ V-493, Dowex® Optipore™ V-502, Dowex® Optipore™ L-285, Dowex® Optipore™ L-323, and Dowex® Optipore™ V-503.Lanxess (formerly Bayer and Sybron): Lewatit® VPOC1064MDPH, Lewatit® VPOC1163, Lewatit® OCEP63, Lewatit® S6328A, Lewatit® OC1066, and Lewatit® 60 / 150MIBK. Mitsubishi Chemical Corporation Corporation): Diaion (registered trademark) HP10, Diaion (registered trademark) HP20, Diaion (registered trademark) HP21, Diaion (registered trademark) HP30, Diaion (registered trademark) HP40, Diaion (registered trademark) HP50, Diaion (registered trademark) SP70, Diaion (registered trademark) SP205, Diaion (registered trademark) SP206, Diaion (registered trademark) SP207, Diaion (registered trademark) SP700, Diaion (registered trademark) SP800, Diaion (registered trademark) SP825 ... Diaion® SP850, Diaion® SP875, Diaion® HP1MG, Diaion® HP2MG, Diaion® CHP55A, Diaion® CHP55Y, Diaion® CHP20A, Diaion® CHP20Y, Diaion® CHP2MGY, Diaion® CHP20P, Diaion® HP20SS, Diaion® SP20SS, and Diaion® SP207SS. Purolite Company: Purosorb™ AP250, and Purosorb™ AP400.
[0174] Aspects of the invention The present invention is illustrated by the following non-limiting embodiments.
[0175] Aspect 1. A method of treating cancer in a subject, comprising treating the subject with a therapeutically effective amount of a porous, biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0176] Aspect 2. A method of treating cancer in a subject in need thereof, comprising administering to the subject a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
[0177] Embodiment 3. The method of embodiment 1 or 2, wherein the adsorbent is administered extracorporeally.
[0178] Embodiment 4. The method of embodiment 1 or 2, wherein said adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0179] Embodiment 5. A method of treating cancer in a subject in need thereof, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0180] Example 6. The method of example 5, wherein said adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0181] Embodiment 7. The method of embodiment 5, wherein the adsorbent is extracorporeal.
[0182] Embodiment 8. The method according to any one of embodiments 2 to 7, wherein the physiological fluid is blood.
[0183] Embodiment 9. A method of treating cancer in a subject in need thereof, comprising providing to the subject a porous biocompatible polymeric adsorbent, The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0184] Aspect 10. The method of any one of Aspects 1-9, wherein the adsorbent comprises a pore structure such that the total pore volume for pore diameters in the range of 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g of dry adsorbent, and the ratio of the pore volume (pore diameters) of the adsorbent from 50 Å to 40,000 Å to the pore volume (pore diameters) of the adsorbent from 1,000 Å to 10,000 Å is less than 2:1.
[0185] Embodiment 11. The method of any one of embodiments 1-10, wherein the adsorbent is made using at least one crosslinker and at least one monomer.
[0186] Aspect 12. The method of aspect 11, wherein the monomers are selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane di ... 13. The process of claim 12, further comprising one or more of the following: pantaerythritol triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
[0187] Embodiment 13. The method of embodiment 11 or 12, wherein the crosslinker comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
[0188] Embodiment 14. The method of any one of embodiments 11-13, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
[0189] Example 15. The method of any one of Examples 1-14, wherein the adsorbent comprises a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
[0190] Aspect 16. The method of any one of Aspects 1 to 15, wherein the adsorbent is administered in combination with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
[0191] Example 17. The method of example 16, wherein said adsorbent is administered prior to or simultaneously with said anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent.
[0192] Example 18. The method of example 16, wherein said adsorbent is administered after administration of said anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent.
[0193] Example 19. The method of example 17 or 18, wherein said anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T-cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
[0194] Embodiment 20. The method of any one of embodiments 1-19, wherein the adsorbent reduces concentrations of one or more of cytokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products in the patient compared to an untreated subject.
[0195] Embodiment 21. The method of any one of embodiments 1 to 20, wherein said method reduces entry of CAR-T cells and other activated cells into the central nervous system compared to untreated subjects.
[0196] Aspect 22. The method of any one of aspects 1 to 20, wherein the method reduces inhibition of the immune system.
[0197] Embodiment 23. The method of any one of embodiments 1 to 20, wherein said method reduces damage due to one or more of cytokine release syndrome (CRS), CAR-T cell associated encephalopathy syndrome (CRES), chimeric antigen receptor T cell therapy associated toxicity (CARTOX), immune effector cell associated neurotoxicity (ICANS), or tumor lysis syndrome (TLS) compared to an untreated subject.
[0198] Aspect 24. The method of any one of Aspects 1 to 23, wherein administration of the adsorbent reduces inhibitors of the immune system before, during, or after administration of the anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent.
[0199] Aspect 25. The method of any one of aspects 1 to 23, wherein administration of the adsorbent removes one or more of: a) cytokines or chemokines, b) soluble checkpoint molecules, and c) extracellular vesicles associated with checkpoint molecules from the subject's bodily fluid.
[0200] Embodiment 26 The method of embodiment 25, wherein said soluble or extracellular vesicle-associated checkpoint molecule is one or more of the examples found in Table 1.
[0201] Embodiment 27. The method of embodiment 25, wherein said cytokine or chemokine comprises one or more members of the interleukin, interferon, tumor growth factor, or tumor necrosis factor family.
[0202] Example 28. The method of any one of Examples 1 to 27, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
[0203] 29. A method of reducing (a) cancer, or (b) inflammation-related complications of cancer therapy or immunotherapy in a subject, comprising administering to the subject a therapeutically effective amount of a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0204] 30. A method of reducing inflammation-related complications of (a) cancer, or (b) cancer treatment or immunotherapy in a subject in need thereof, comprising administering to the subject a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
[0205] Aspect 31. The method of aspect 29 or 30, wherein the adsorbent is administered extracorporeally.
[0206] Embodiment 32. The method of embodiment 29 or 30, wherein said adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0207] Aspect 33. A method of reducing (a) cancer, or (b) inflammation-related complications of cancer therapy or immunotherapy in a subject in need thereof, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0208] Example 34. The method of example 33, wherein said contacting step comprises administering said adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0209] Aspect 35. The method of aspect 33, wherein the adsorbent is extracorporeal.
[0210] Embodiment 36. The method according to any one of embodiments 30 to 35, wherein the physiological fluid is blood.
[0211] Embodiment 37. A method of reducing inflammation-related complications of (a) cancer, or (b) cancer therapy or immunotherapy in a subject in need thereof, comprising providing to the subject a porous biocompatible polymeric adsorbent, The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0212] Embodiment 38. The method according to any one of embodiments 29 to 37, wherein the method reduces inflammation-related complications of cancer.
[0213] Aspect 39. The method according to any one of aspects 29 to 37, wherein the method reduces inflammation caused by cancer treatment.
[0214] Embodiment 40 The method according to any one of embodiments 29 to 37, wherein the method reduces inflammation caused by immunotherapy.
[0215] Embodiment 41. The method of embodiment 39 or 40, wherein said cancer therapy or immunotherapy comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T-cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
[0216] Embodiment 42. The method according to any one of embodiments 38 to 40, wherein reducing inflammation ameliorates one or more of the onset, severity, or progression of cachexia.
[0217] Embodiment 43. The method of any one of embodiments 29 to 42, wherein said method reduces entry of CAR-T cells and other activated cells into the central nervous system compared to an untreated subject.
[0218] Embodiment 44. The method of any one of embodiments 29 to 42, wherein said method reduces damage due to one or more of cytokine release syndrome (CRS), CAR-T cell associated encephalopathy syndrome (CRES), chimeric antigen receptor T cell therapy associated toxicity (CARTOX), immune effector cell associated neurotoxicity (ICANS), or tumor lysis syndrome (TLS) compared to an untreated subject.
[0219] Embodiment 45. The method of any one of embodiments 29 to 42, wherein the adsorbent reduces concentrations of one or more of cytokines, chemokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products in the patient compared to an untreated subject.
[0220] Embodiment 46. The method of any one of embodiments 29-45, wherein the adsorbent comprises a pore structure such that the total pore volume of pore diameters in the range of 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g of dry adsorbent, and the ratio of the pore volume (pore diameter) of the adsorbent from 50 Å to 40,000 Å to the pore volume (pore diameter) from 1,000 Å to 10,000 Å is less than 2:1.
[0221] Embodiment 47. The method of any one of embodiments 29-46, wherein the adsorbent is prepared using at least one crosslinker and at least one monomer.
[0222] Aspect 48. The method of aspect 47, wherein the monomers are selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane tri ... acrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, and mixtures thereof.
[0223] Aspect 49. The method of aspect 47 or 48, wherein the crosslinker comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
[0224] Embodiment 50. The method of any one of embodiments 47-49, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
[0225] Example 51. The method of any one of Examples 29-50, wherein the adsorbent comprises a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
[0226] Example 52. The method of any one of Examples 29-51, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
[0227] Aspect 53. A method of improving immune system function in a subject before, during, or after treatment with an anti-cancer agent, an anti-cancer therapeutic agent, and / or an immunotherapeutic agent, comprising administering to the subject a therapeutically effective amount of a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0228] Aspect 54. A method of improving immune system function in a subject in need thereof before, during, or after treatment with an anti-cancer agent, an anti-cancer therapeutic agent, and / or an immunotherapeutic agent, comprising administering to the subject a therapeutically effective amount of a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
[0229] Embodiment 55. The method of embodiment 53 or 54, wherein the adsorbent is administered extracorporeally.
[0230] Embodiment 56. The method of embodiment 53 or 54, wherein said adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0231] Aspect 57. A method of improving immune system function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0232] Embodiment 58. The method of embodiment 57, wherein said contacting step comprises administering said adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0233] Aspect 59. The method of aspect 57, wherein the adsorbent is extracorporeal.
[0234] Embodiment 60. The method according to any one of embodiments 54 to 59, wherein the physiological fluid is blood.
[0235] Aspect 61. A method of improving immune system function in a subject in need thereof before, during, or after treatment with an anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent, comprising providing to the subject a porous biocompatible polymeric adsorbent; The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0236] Embodiment 62. The method of any one of embodiments 53-61, wherein the adsorbent comprises a pore structure such that the total pore volume of pore diameters in the range of 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g of dry adsorbent, and the ratio of the pore volume (pore diameter) of the adsorbent from 50 Å to 40,000 Å to the pore volume (pore diameter) of the adsorbent from 1,000 Å to 10,000 Å is less than 2:1.
[0237] Embodiment 63. The method of any one of embodiments 53 to 62, wherein the adsorbent is prepared using at least one crosslinker and at least one monomer.
[0238] Aspect 64. The method of aspect 63, wherein the monomers are selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane tri ... acrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, and mixtures thereof.
[0239] Aspect 65. The method of aspect 63 or 64, wherein the crosslinker comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
[0240] Embodiment 66. The method of any one of embodiments 63-65, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
[0241] Example 67. The method of any one of Examples 53 to 66, wherein the adsorbent comprises a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
[0242] Embodiment 68. The method of any one of embodiments 53 to 67, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
[0243] Aspect 69. The method of any one of aspects 53 to 68, wherein the anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
[0244] Embodiment 70. The method according to any one of embodiments 53 to 69, wherein the method improves immune system function in a subject in need thereof prior to treatment with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
[0245] Embodiment 71. The method according to any one of embodiments 53 to 69, wherein the method improves immune system function in a subject in need thereof during treatment with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
[0246] Embodiment 72. The method according to any one of embodiments 53 to 69, wherein the method improves immune system function in a subject in need thereof following treatment with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
[0247] Embodiment 73. A method according to any one of embodiments 70 to 72, wherein administration of the adsorbent removes one or more of: a) cytokines or chemokines, b) soluble checkpoint molecules, and c) extracellular vesicles associated with checkpoint molecules from the subject's bodily fluid.
[0248] Embodiment 74. The method of embodiment 73, wherein said soluble or extracellular vesicle-associated checkpoint molecule is one or more of the examples found in Table 1.
[0249] Embodiment 75. The method of embodiment 73, wherein said cytokine or chemokine comprises one or more members of the interleukin, interferon, tumor growth factor, or tumor necrosis factor family.
[0250] Embodiment 76. The method according to any one of embodiments 53, 54, 57, or 61, wherein the improvement of immune system function comprises a reduction in systemic or local immunosuppression.
[0251] Embodiment 77. The method according to any one of embodiments 53, 54, 57, or 61, wherein the improved immune system function comprises a reduction in systemic or local excessive inflammation.
[0252] 78. A method for improving the efficacy of cancer therapy or immunotherapy in a subject, comprising treating the subject with a therapeutically effective amount of a porous biocompatible polymeric adsorbent, The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0253] A method for improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof, comprising administering to the subject a porous biocompatible polymeric adsorbent, The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
[0254] Embodiment 80. The method of embodiment 78 or 79, wherein the adsorbent is administered extracorporeally.
[0255] Embodiment 81. The method of embodiment 78 or 79, wherein said adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0256] 82. A method for improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent, The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0257] Embodiment 83. The method of embodiment 82, wherein said contacting step comprises administering said adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
[0258] Aspect 84. The method of aspect 82, wherein the adsorbent is extracorporeal.
[0259] Embodiment 85. The method according to any one of embodiments 79 to 84, wherein the physiological fluid is blood.
[0260] A method for improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof, comprising providing to said subject a porous biocompatible polymeric adsorbent, The adsorbent comprises a pore diameter in the range of between about 50 Å and about 3000 Å and a pore volume of between about 0.5 cc / g and about 3.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
[0261] Embodiment 87. The method of any one of embodiments 78-86, wherein the adsorbent comprises a pore structure such that the total pore volume of pore diameters in the range of 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g of dry adsorbent, and the ratio of the pore volume (pore diameter) of the adsorbent from 50 Å to 40,000 Å to the pore volume (pore diameter) from 1,000 Å to 10,000 Å is less than 2:1.
[0262] Embodiment 88. The method of any one of embodiments 78 to 87, wherein the adsorbent is prepared using at least one cross-linking agent and at least one monomer.
[0263] Aspect 89. The method of aspect 88, wherein the monomers are selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane tri ... acrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, and mixtures thereof.
[0264] Aspect 90. The method of aspect 88 or 89, wherein the crosslinker comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
[0265] Embodiment 91. The method of any one of embodiments 88-90, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
[0266] Example 92. The method of any one of Examples 78 to 91, wherein the adsorbent comprises a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
[0267] Example 93. The method of any one of Examples 78 to 92, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
[0268] Embodiment 94. The method according to any one of embodiments 78 to 93, wherein the cancer treatment or immunotherapy comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
[0269] Aspect 95. The method according to any one of aspects 78 to 94, wherein the method improves the efficacy of the cancer treatment.
[0270] Aspect 96. The method according to any one of aspects 78 to 94, wherein the method improves the efficacy of the immunotherapy.
[0271] Aspect 97. The method of any one of aspects 78 to 96, wherein the adsorbent reduces concentrations of one or more of cytokines, chemokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products in the patient compared to an untreated subject.
[0272] Embodiment 98. The method according to any one of embodiments 78 to 96, wherein the method reduces entry of CAR-T cells and other activated cells into the central nervous system compared to an untreated subject.
[0273] Aspect 99. The method of any one of aspects 78 to 96, wherein the method reduces damage caused by one or more of cytokine release syndrome (CRS), CAR-T cell associated encephalopathy syndrome (CRES), chimeric antigen receptor T cell therapy associated toxicity (CARTOX), immune effector cell associated neurotoxicity (ICANS), or tumor lysis syndrome (TLS) compared to an untreated subject.
[0274] Embodiment 100. The method according to any one of embodiments 78 to 96, wherein said method ameliorates one or more of the onset, severity, or progression of cachexia.
[0275] Embodiment 101. A method according to any one of embodiments 78 to 96, wherein administration of the adsorbent removes one or more of: a) cytokines or chemokines, b) soluble checkpoint molecules, and c) extracellular vesicles associated with checkpoint molecules from the subject's bodily fluid.
[0276] Embodiment 102. The method of embodiment 101, wherein the soluble or extracellular vesicle-associated checkpoint molecule is one or more of the examples found in Table 1.
[0277] Embodiment 103. The method of embodiment 101, wherein said cytokine or chemokine comprises one or more members of the interleukin, interferon, tumor growth factor, or tumor necrosis factor family.
[0278] Working Example The following examples are intended to be illustrative and non-limiting. The following examples of the present invention are intended to further illustrate the nature of the present invention. It is believed that one skilled in the art can use the above description and the following illustrative examples to make and use the present invention and to carry out the claimed method. It should be understood that the following examples do not limit the present invention, and the scope of the present invention is determined by the appended claims. EXAMPLES
[0279] Example 1: Synthesis of basic adsorbents CY14175 & CY15077 Reactor Setup: A 3 L jacketed cylindrical glass reactor was fitted with a 4-neck glass lid using stainless steel flange clamps and a PTFE gasket. The lid was fitted with a PTFE stirrer bearing, an RTD adapter, and a water-cooled reflux condenser. A stainless steel stirrer shaft with five 60° bars was threaded through the stirrer bearing and inserted into a digital overhead stirrer. The RTD was threaded through a corresponding adapter and connected to a PolyStat circulating heating and cooling unit. Matching tubing was used to connect the reactor jacket inlet and outlet to the appropriate ports on the PolyStat. The unused port on the lid was used to charge the reactor and was otherwise plugged in.
[0280] Polymerization: The compositions of the aqueous and organic phases are shown below in Tables 2 and 3, respectively. Ultrapure water was split into approximately equal amounts in two separate Erlenmeyer flasks containing PTFE-coated magnetic stir bars. Polyvinyl alcohol (PVA), with a degree of hydrolysis of 85.0-89.0 mol% and a viscosity of 23.0-27.0 cP for a 4% aqueous solution at 20°C, was dispersed in water in the first flask and heated to 80°C with stirring on a hot plate. Salts (see Table 2, MSP, DSP, TSP, and sodium nitrite) were dispersed in water in the second flask and heated to 80°C with stirring on a hot plate. Circulation of heat transfer medium from PolyStat through the reactor jacket was started, heating the fluid temperature to 60°C. Once the PVA and salts were dissolved, both solutions were charged into the reactor, one at a time, using a glass funnel. The digital overhead stirrer was turned on and the RPM was set to a value that would form the appropriate droplet size upon addition of the organic phase. The temperature of the aqueous phase in the kettle was set at 70°C. The organic phase was prepared by adding benzoyl peroxide (BPO) to divinylbenzene (DVB) in a 2 L Erlenmeyer flask and stirring until completely dissolved. 2,2,4-trimethylpentane and toluene were added to the flask and shaken to mix well. Once the temperature of the aqueous phase in the reactor reached 70°C, the organic phase was charged to the reactor using a fine-necked glass funnel. The temperature of the reactor was decreased simultaneously with the addition of the organic phase. The PolyStat temperature program was started and the reactor was heated from 60°C to 77°C over 30 minutes, from 77°C to 80°C over 30 minutes, held at 80°C for 960 minutes, and cooled to 20°C over 60 minutes. TIFF2024542593000004.tif34141TIFF2024542593000005.tif30141
[0281] Workup: The reaction volume level in the reactor was marked. The overhead stirrer was stopped, residual liquid was siphoned off from the reactor, and the reactor was filled to the mark with ultrapure water at room temperature. The overhead stirrer was restarted and the slurry was heated to 70°C as quickly as possible. After 30 minutes, the stirring was stopped and residual liquid was siphoned off. In this manner, the polymer beads were washed five times. During the last wash, the temperature of the slurry was cooled to room temperature. After the final water wash, the polymer beads were washed with 99% isopropyl alcohol (IPA) in the same manner. After siphoning off the 99% IPA and replacing it with 70% IPA, the slurry was transferred to a clean 4 L glass container. Unless otherwise noted, the polymer was steam stripped in a stainless steel tube for 8 hours, rewetted with 70% IPA, transferred to pure water, sieved to obtain only the bead portion with a diameter of 300-600 μm, and dried at 100°C until no weight loss was observed due to drying.
[0282] The cumulative pore volume data for polymers CY14175 and CY15077, measured by nitrogen desorption isotherm and mercury intrusion porosimetry, are shown below in Tables 4 and 5, respectively. TIFF2024542593000006.tif74141TIFF2024542593000007.tif153141 EXAMPLES
[0283] Example 2: Removal of soluble PD-L1 (PD-L1) from bovine whole blood Benchtop evaluation data demonstrated that Cytosorb removes soluble PD-L1 (sPD-L1) from bovine whole blood, as shown in Figure 1. Cytosorb was evaluated in this study at two volumes: 60 mL and 120 mL. The starting PD-L1 concentration was 1.4 ng / mL in 800 mL of bovine whole blood. Blood was recirculated through the Cytosorb device at a rate of 60 mL / min. After 6 hours, 60 mL of Cytosorb removed 49% of the starting sPD-L1 concentration, and 120 mL of Cytosorb removed 76% of the starting sPD-L1 concentration. A control (placebo, no Cytosorb) was evaluated simultaneously with each Cytosorb experiment. Each group was repeated three times (n=3).
[0284] As mentioned above, soluble PD-L1 and soluble PD-L2 ligands activate the PD-1 receptor on cytotoxic T cells, reducing T cell activity and preventing cell-mediated killing of cancer. Therefore, this example shows that the biocompatible polymeric adsorbent of the present invention can be used to treat cancer. EXAMPLES
[0285] Example 3: Demonstration of antitumor efficacy of porous biocompatible polymeric adsorbents by intratumoral or subcutaneous injection in small animal solid tumor models A suitable small animal model is injected with the cancer cells to be tested to induce tumor growth. After the tumor has grown, porous polymer beads suspended in a suitable matrix (e.g., saline) are injected into the tumor and blood samples are taken at various time points to analyze the reduction of cytokines and soluble or extracellular vesicle-associated checkpoint molecules. The tumor is also observed to detect the reduction of tumor growth. The weight change of the animals is compared to untreated animals.
[0286] For example, C57BL / 6 mice were inoculated with B16-F10 mouse tumor cells (0.5 × 10 6). After tumor growth is established, subcutaneously inject the tumor site with a porous biocompatible polymer adsorbent (1 mL, suspended in saline), or saline alone (control). Record the animal's weight on day 1 prior to dosing, and on days 3, 5, 7, and 9. On days 1, 3, 5, 7, and 9 after cell inoculation, sacrifice six animals from each dosing group by cardiac puncture to collect a maximum amount of blood (0.6-1.0 mL), and separate plasma to analyze for cytokines (e.g., MCP-1, GM-CSF, IFN-b, IFN-g, IL-1a, IL-1b, IL-6, IL-10, IL-12(p70), IL-17A, IL-23, IL-27, TNF-a) and soluble checkpoint molecules (e.g., sPD-L1) using appropriate ELISA / multiplex assays. Extracellular vesicle (EV)-associated checkpoint molecules (e.g., EV-associated PD-L1) are also analyzed after EV collection using standard procedures. Furthermore, on specific days (e.g., 1, 3, 5, 7, and 9), lungs are harvested and fixed in Bouin's fluid for histopathological examination, lungs are photographed, and metastatic lesions are counted. EXAMPLES
[0287] Example 4: Demonstration of the antitumor effect of a porous biocompatible polymeric adsorbent by ex vivo treatment in a small animal cancer model The cancer cells to be tested are injected into an appropriate small animal model to induce tumor growth. After tumor growth, the test animals are explanted with a porous biocompatible polymeric adsorbent and blood samples are taken at various time points to analyze the reduction of cytokines and chemokines, as well as soluble or extracellular vesicle-associated checkpoint molecules. The tumors are also monitored to detect the reduction in tumor growth. The weight change of the animals is compared to non-treated animals.
[0288] For example, Wistar rats (n = 6) were treated with 8 × 10 7Spleen cells are injected intravenously. The percentage of CD19+CD5+ chronic lymphocytic leukemia (CLL) cells should be at least 80% of the total viable lymphocytes. A 6-hour extracorporeal treatment with a porous biocompatible polymer adsorbent is performed on days 1-6 after injection. A control group of rats (n=6) receives extracorporeal treatment without the adsorbent connected to the extracorporeal circuit. Blood samples are taken on day 1 (0, 2, 4, 6, 24 hours) and once a day from day 2 until the end of the study. The end of the study is determined by the time when the control rats are judged to have a fully leukemic state that meets the established criteria for CLL (e.g., after 30 days). At the end of the study, peripheral blood is collected by cardiac puncture using EDTA as an anticoagulant. Spleen sections are embedded in paraffin and stained with hematoxylin and eosin (HE) and antibodies against CD5 and B220. Plasma for analysis will be collected and cytokines (e.g., CCL2, IL-10, GM-CSF, CXCL2, CXCL5, and TNF-α) will be analyzed at all time points by multiplex assays. Plasma levels of soluble checkpoint molecules (e.g., sPD-L1 and sPD-L2) will be measured by ELISA, and extracellular vesicle-associated checkpoint molecules (e.g., EV-associated PD-L1) will also be analyzed after EV collection using standard procedures. EXAMPLES
[0289] Example 5: Evaluation of removal of soluble checkpoint inhibitor protein molecules from cytosorbs using whole bovine blood in a small-scale benchtop recirculation test Objective: To evaluate the efficiency of Cytosorb in removing 11 soluble ligands sPD-L1, sCTLA-4, sLAG-3, sTIM-3, sPD-1, sPD-L2, sICOS, and sVISTA from circulating bovine whole blood in a small-scale recirculation setup using 60 mL of Cytosorb at a flow rate of 60 mL / min.
[0290] Experiment 1a: A mixture of the checkpoint molecules sPD-L1, sCTLA-4, sLAG-3, and sTIM-3 was added to blood at starting concentrations of 1400, 2000, 3000, and 4000 pg / mL, respectively, and the removal rate by Cytosorb was evaluated.
[0291] Experiment 1b: A mixture of the checkpoint molecules sPD-1, sPD-L2, sICOS, and sVISTA was added to blood at starting concentrations of 2000, 5000, 2000, and 2000 pg / mL, respectively, and the removal rates by Cytosorb were evaluated.
[0292] Rationale: Starting plasma concentrations in these studies were based on clinically relevant maximum plasma concentrations found in the literature. [Zhao,J.etal.Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.Medicine(Baltimore)96,e6102(2017);Zhou,J.etal.Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.Cancer Immunol Res 5,480-492(2017);Botticelli,A.et al.The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer:A Pilot Study.J Pers Med 11(2021);Keane,C.et al.LAG3:a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.Blood Adv 4,1367-1377(2020);Shapiro,M.et al.Lymphocyte activation gene 3:a novel therapeutic target in chronic lymphocytic leukemia.Haematologica 102,874-882(2017);Odagiri,N.et al.Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization.Cancers(Basel)12(2020);Xie,C.et al.Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4 / NF-kappaB pathway.Sci Rep 6,27528(2016);Noubissi Nzeteu,G.A.et al.Macrophage Differentiation and Polarization Regulate the Release of the Immune Checkpoint Protein V-Domain Ig Suppressor of T Cell Activation.Front Immunol 13,837097(2022).].
[0293] The selection of analytes (sPD-L1, sTIM-3, sLAG-3, sCTLA-4, sPD-1, sPD-L2, sICOS, sVISTA) was based on their colocalization in clinical samples in common cancer types. Of note, preclinical studies have demonstrated that blocking LAG-3 alone does not restore T cell exhaustion, whereas combined LAG-3 / PD-1 blockade reduces tumor burden [Hinshaw,et al.The Tumor Microenvironment Innately Modulates Cancer Progression.Cancer Res 79,4557-4566(2019)]. This indicates that a more broad ablation of checkpoint molecules may prove to be of greater clinical relevance than targeting a single checkpoint molecule. This is consistent with the fact that many clinical trials are ongoing testing bispecific antibodies as checkpoint inhibitors, such as LAG-3 / PD-L1, LAG-3 / TIM-3, or VISTA / PD-L1 combinations, to treat various cancer types in which these combinations coexist. [Lee,et al.Clinical Insights Into Novel Immune Checkpoint Inhibitors.Front Pharmacol 12,681320(2021).]
[0294] Results and Discussion Figure 2A shows the survival rates of four proteins (sCTLA-4, sTIM-3, sLAG-3, and sPD-L1) during 6 hours of hemoperfusion with Cytosorb in a benchtop recirculation small-scale experiment. Figure 2B shows the survival rates of four proteins (sPD-1, sPD-L2, sVISTA, and sICOS) during 6 hours of hemoperfusion with Cytosorb in a benchtop recirculation small-scale experiment.
[0295] Data are presented as percentage of baseline (0 h time point) for each protein for both control and treatment circuits as an average of three experiments. The results for the control circuit show that the tested proteins were stable over a 6 h period where the percentage of measured baseline remained between 85-110% (Figure 2A, 2B). Therefore, the reduced survival of these proteins in the cytosorb group is solely attributable to their removal by the cytosorb beads. The multiplex data revealed that survival after 6 h ranged from 20-56% in the cytosorb group, and the differences between the control and cytosorb groups after 6 h for each protein were significant (p<0.05) (except for PD-1, which was only performed in two replicates, which did not allow for statistical testing).
[0296] Specifically, mean clearance rates at the end of 6 hours of hemoperfusion with Cytosorb were measured as follows: VISTA (80%), LAG-3 (76%), ICOS (68%), TIM-3 (63%), sPD-L2 (56%), sPD-L1 (49%), sCTLA-4 (46%), and sPD-1 (44%).
[0297] Removal by Cytosorb depends on a variety of factors, including 1) molecular weight, 2) concentration, and 3) molecular structure. In this experiment, we utilized a mixture of multiple checkpoint molecules to better mimic the clinical situation in which multiple checkpoint molecules are circulating simultaneously. Some of the molecules present simultaneously are expected to undergo receptor-ligand binding during the experiment, particularly sPD-1 and PDL-2. Given the factors above, one would expect each molecule to be removed when present alone, but significant removal was observed for sPD-1 and sPD-L2 despite their simultaneous presence and despite the presence of excess ligands that promote binding to their cognate receptors. Nevertheless, robust removal of sPD-1 was achieved. Removal can be enhanced by increasing the dose of Cytosorb and / or extending treatment beyond 6 hours (see Figure 2A, 2B). EXAMPLES
[0298] Example 6: Use of bioabsorbable porous polymeric materials for intratumoral, subcutaneous, topical, injectable and oral applications for cancer treatment by adsorption of soluble immune checkpoint molecules and / or cytokines Bioabsorbable porous polymeric materials that exhibit desirable degradation profiles with highly biocompatible and safe degradation products can be used in the treatment of cancer by local injection into tumors, intravenous injection into blood cancers, oral application into intestinal and gastric cancers, and topical and subcutaneous application into skin cancers such as melanoma.
[0299] An example is poly(lactic-co-glycolic acid) [PLGA]-based porous nanoparticles, macroparticles, or microparticles. These porous particles can be modified with various ligands or porogens to enhance the adsorption of specific proteins. The degradation profile of these resorbable polymers varies from hours to months to years depending on the type of application. Other bioabsorbable polymers include polyesters, polyanhydrides, polycaprolactones, polytrioxanes, polycarbonates, and combinations thereof. These porous particles adsorb soluble immune checkpoint protein molecules from the systemic circulation or local tumor environment and inhibit the interaction between the soluble and membrane-bound forms, thereby preventing cancer cells from activating T cells to escape the immune response. These porous resorbable particles can be tested for the treatment of various types of cancer using the methods described in Examples 3 and 4. EXAMPLES
[0300] Example 7: Use of Adsorbent Polymers to Remove Excess Inflammatory Mediators and Checkpoint Molecules to Reduce Inflammation-Related Complications and Improve the Efficacy of Hyper / Hypothermic Cancer Therapy Application of the adsorbent before, during, and / or after hyper / hypothermia treatment removes cytokines, chemokines, soluble checkpoint molecules, and other inflammatory factors that may interfere with the efficacy or tolerability of cancer treatment. For example, application of the adsorbent before hyper / hypothermia removes anti-inflammatory cytokines such as IL-10 and TGF-β and soluble checkpoint molecules such as sPD-L1 that mediate a tumor-protective environment, thereby improving tumor lysis and immune-mediated apoptosis of cancer cells when hyper / hypothermia is applied. When the adsorbent is applied during hyper / hypothermia, it removes excess inflammatory factors, including IL-6 and TNF-α, induced by the treatment that would otherwise damage healthy tissues, improving the tolerability of the treatment. Adsorbents applied after hyper / hypothermia can remove inflammatory factors and damage-associated molecular patterns released with continued apoptosis of cancer cells after treatment, preventing the development of cytokine release syndrome (CRS) and tumor lysis syndrome (TLR).
[0301] While a number of embodiments of the invention have been described, it will be apparent that the basic examples can be modified to provide other embodiments which utilize the compounds and methods of the invention. It will therefore be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments exemplified.
Claims
1. 1. A method of treating cancer in a subject, comprising treating the subject with a therapeutically effective amount of a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
2. 1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
3. The method of claim 1 or 2, wherein the adsorbent is administered extracorporeally.
4. 3. The method of claim 1 or 2, wherein the adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
5. 1. A method of treating cancer in a subject in need thereof, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
6. 6. The method of claim 5, wherein the adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
7. The method of claim 5, wherein the adsorbent is extracorporeal.
8. The method of any one of claims 2 to 7, wherein the physiological fluid is blood.
9. 1. A method of treating cancer in a subject in need thereof, comprising providing to the subject a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
10. 10. The method of any one of claims 1 to 9, wherein the adsorbent comprises a pore structure such that the total pore volume in the range of pore diameters from 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g dry adsorbent, and the ratio of the pore volume (pore diameter) from 50 Å to 40,000 Å to the pore volume (pore diameter) from 1,000 Å to 10,000 Å of the adsorbent is less than 2:
1.
11. The method of any one of claims 1 to 10, wherein the adsorbent is prepared using at least one cross-linking agent and at least one monomer.
12. 12. The method of claim 11, wherein the monomer is selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane 13. The method of claim 12, further comprising the step of: one or more of a tert-butyl ether copolymer, ...
13. 13. The method of claim 11 or 12, wherein the crosslinking agent comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
14. The method according to any one of claims 11 to 13, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
15. The method of any one of claims 1 to 14, wherein the adsorbent comprises a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
16. The method of any one of claims 1 to 15, wherein the adsorbent is administered in combination with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
17. 17. The method of claim 16, wherein the adsorbent is administered prior to or simultaneously with the anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent.
18. 17. The method of claim 16, wherein the adsorbent is administered after administration of the anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent.
19. 19. The method of claim 17 or 18, wherein the anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
20. 20. The method of any one of claims 1-19, wherein the adsorbent reduces concentrations of one or more of cytokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products in the patient compared to an untreated subject.
21. 21. The method of any one of claims 1-20, wherein the method reduces entry of CAR-T cells and other activated cells into the central nervous system compared to an untreated subject.
22. The method of any one of claims 1 to 20, wherein the method reduces inhibition of the immune system.
23. 21. The method of any one of claims 1-20, wherein the method reduces damage due to one or more of cytokine release syndrome (CRS), CAR-T cell associated encephalopathy syndrome (CRES), chimeric antigen receptor T cell therapy associated toxicity (CARTOX), immune effector cell associated neurotoxicity (ICANS), or tumor lysis syndrome (TLS) compared to an untreated subject.
24. 24. The method of any one of claims 1 to 23, wherein administration of the adsorbent reduces inhibitors of the immune system before, during, or after administration of the anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent.
25. The method of any one of claims 1 to 23, wherein administration of the adsorbent removes one or more of: a) cytokines or chemokines, b) soluble checkpoint molecules, and c) extracellular vesicles associated with checkpoint molecules from the subject's body fluid.
26. 26. The method of claim 25, wherein the soluble or extracellular vesicle-associated checkpoint molecule is one or more of the examples found in Table 1.
27. 26. The method of claim 25, wherein the cytokine or chemokine comprises one or more members of the interleukin, interferon, tumor growth factor, or tumor necrosis factor family.
28. 28. The method of any one of claims 1 to 27, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
29. 1. A method of reducing (a) cancer, or (b) inflammation-related complications of cancer therapy or immunotherapy in a subject, comprising treating said subject with a therapeutically effective amount of a porous, biocompatible, polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
30. 1. A method of reducing (a) cancer, or (b) inflammation-related complications of cancer treatment or immunotherapy in a subject in need thereof, comprising administering to the subject a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
31. 31. The method of claim 29 or 30, wherein the adsorbent is administered extracorporeally.
32. 31. The method of claim 29 or 30, wherein the adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
33. 1. A method of reducing (a) cancer, or (b) inflammation-related complications of cancer therapy or immunotherapy in a subject in need thereof, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
34. 34. The method of claim 33, wherein the contacting step comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
35. 34. The method of claim 33, wherein the adsorbent is extracorporeal.
36. The method of any one of claims 30 to 35, wherein the physiological fluid is blood.
37. 1. A method of reducing inflammation-related complications of (a) cancer, or (b) cancer treatment or immunotherapy in a subject in need thereof, comprising providing to the subject a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume between about 0.5 cc / g and about 5.0 cc / g dry polymer.
38. 38. The method of any one of claims 29 to 37, wherein the method reduces inflammation-related complications of cancer.
39. 38. The method of any one of claims 29 to 37, wherein the method reduces inflammation caused by cancer treatment.
40. 38. The method of any one of claims 29 to 37, wherein the method reduces inflammation caused by immunotherapy.
41. 41. The method of claim 39 or 40, wherein the cancer therapy or immunotherapy comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
42. 41. The method of any one of claims 38-40, wherein reducing inflammation ameliorates one or more of the onset, severity, or progression of cachexia.
43. 43. The method of any one of claims 29-42, wherein the method reduces entry of CAR-T cells and other activated cells into the central nervous system compared to an untreated subject.
44. 43. The method of any one of claims 29-42, wherein the method reduces damage due to one or more of cytokine release syndrome (CRS), CAR-T cell associated encephalopathy syndrome (CRES), chimeric antigen receptor T cell therapy associated toxicity (CARTOX), immune effector cell associated neurotoxicity (ICANS), or tumor lysis syndrome (TLS) compared to an untreated subject.
45. 43. The method of any one of claims 29-42, wherein the adsorbent reduces concentrations of one or more of cytokines, chemokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products in the patient compared to an untreated subject.
46. 46. The method of any one of claims 29-45, wherein the adsorbent comprises a pore structure such that the total pore volume in the range of pore diameters from 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g dry adsorbent, and the ratio of the pore volume (pore diameter) from 50 Å to 40,000 Å to the pore volume (pore diameter) from 1,000 Å to 10,000 Å of the adsorbent is less than 2:
1.
47. The method of any one of claims 29 to 46, wherein the adsorbent is prepared using at least one cross-linking agent and at least one monomer.
48. 48. The method of claim 47, wherein the monomer is selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane trimeth ... acrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, and mixtures thereof.
49. 49. The method of claim 47 or 48, wherein the crosslinker comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
50. 50. The method of any one of claims 47 to 49, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
51. The method of any one of claims 29-50, wherein the adsorbent includes a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
52. 52. The method of any one of claims 29 to 51, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
53. 1. A method of improving immune system function in a subject before, during, or after treatment with an anti-cancer agent, an anti-cancer therapeutic agent, and / or an immunotherapeutic agent, comprising administering to the subject a therapeutically effective amount of a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
54. 1. A method of improving immune system function in a subject in need thereof before, during, or after treatment with an anti-cancer agent, an anti-cancer therapeutic agent, and / or an immunotherapeutic agent, comprising administering to the subject a therapeutically effective amount of a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
55. 55. The method of claim 53 or 54, wherein the adsorbent is administered extracorporeally.
56. 55. The method of claim 53 or 54, wherein the adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
57. 1. A method of improving immune system function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
58. 58. The method of claim 57, wherein the contacting step comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
59. 58. The method of claim 57, wherein the adsorbent is extracorporeal.
60. 60. The method of any one of claims 54 to 59, wherein the physiological fluid is blood.
61. 1. A method of improving immune system function in a subject in need thereof before, during, or after treatment with an anti-cancer, anti-cancer therapeutic, or immunotherapeutic agent, comprising providing to the subject a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
62. 62. The method of any one of claims 53-61, wherein the adsorbent comprises a pore structure such that the total pore volume in the range of pore diameters from 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g dry adsorbent, and the ratio of the pore volume (pore diameter) from 50 Å to 40,000 Å to the pore volume (pore diameter) from 1,000 Å to 10,000 Å of the adsorbent is less than 2:
1.
63. 63. The method of any one of claims 53 to 62, wherein the adsorbent is prepared using at least one cross-linking agent and at least one monomer.
64. 64. The method of claim 63, wherein the monomer is selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane trimeth ... acrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, and mixtures thereof.
65. 65. The method of claim 63 or 64, wherein the crosslinker comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
66. 66. The method of any one of claims 63 to 65, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
67. 67. The method of any one of claims 53-66, wherein the adsorbent includes a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
68. 68. The method of any one of claims 53 to 67, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
69. 69. The method of any one of claims 53-68, wherein the anti-cancer agent, anti-cancer therapeutic agent, or immunotherapeutic agent comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
70. 70. The method of any one of claims 53-69, wherein the method improves immune system function in a subject in need thereof prior to treatment with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
71. 70. The method of any one of claims 53-69, wherein the method improves immune system function in a subject in need thereof during treatment with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
72. 70. The method of any one of claims 53-69, wherein the method improves immune system function in a subject in need thereof following treatment with an anti-cancer agent, an anti-cancer therapeutic agent, or an immunotherapeutic agent.
73. The method of any one of claims 70 to 72, wherein administration of the adsorbent removes one or more of: a) cytokines or chemokines, b) soluble checkpoint molecules, and c) extracellular vesicles associated with checkpoint molecules from the subject's bodily fluid.
74. 74. The method of claim 73, wherein the soluble or extracellular vesicle-associated checkpoint molecule is one or more of the examples found in Table 1.
75. 74. The method of claim 73, wherein the cytokine or chemokine comprises one or more members of the interleukin, interferon, tumor growth factor, or tumor necrosis factor family.
76. 62. The method of any one of claims 53, 54, 57, or 61, wherein the improved immune system function comprises a reduction in systemic or local immunosuppression.
77. 62. The method of any one of claims 53, 54, 57, or 61, wherein the improved immune system function comprises a reduction in systemic or localized excessive inflammation.
78. 1. A method for improving the effectiveness of cancer therapy or immunotherapy in a subject, comprising treating the subject with a therapeutically effective amount of a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
79. 1. A method for improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof, comprising administering to the subject a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer; The method, wherein the administering step contacts the adsorbent with a physiological fluid of the subject.
80. 80. The method of claim 78 or 79, wherein the adsorbent is administered extracorporeally.
81. 80. The method of claim 78 or 79, wherein the adsorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
82. 1. A method for improving the effectiveness of cancer therapy or immunotherapy in a subject in need thereof, comprising contacting a physiological fluid of the subject with a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or The method of claim 1, wherein the adsorbent comprises a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
83. 83. The method of claim 82, wherein the contacting step comprises administering the adsorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, topically, orally, nasally, via a feeding tube, or rectally.
84. 83. The method of claim 82, wherein the adsorbent is extracorporeal.
85. 85. The method of any one of claims 79 to 84, wherein the physiological fluid is blood.
86. 1. A method for improving the efficacy of cancer therapy or immunotherapy in a subject in need thereof, comprising providing to said subject a porous biocompatible polymeric adsorbent; the adsorbent comprises a pore diameter ranging between about 50 Å and about 3000 Å and a pore volume between about 0.5 cc / g and about 3.0 cc / g dry polymer; or the adsorbent comprises a pore diameter ranging between about 50 Å and about 10,000 Å and a pore volume between about 0.5 cc / g and about 4.0 cc / g dry polymer; or said adsorbent comprising a pore diameter ranging between about 50 Å and about 40,000 Å and a pore volume ranging between about 0.5 cc / g and about 5.0 cc / g dry polymer.
87. 87. The method of any one of claims 78-86, wherein the adsorbent comprises a pore structure such that the total pore volume in the range of pore diameters from 50 Å to 40,000 Å is greater than 0.5 cc / g to 5.0 cc / g dry adsorbent, and the ratio of the pore volume (pore diameter) from 50 Å to 40,000 Å to the pore volume (pore diameter) from 1,000 Å to 10,000 Å of the adsorbent is less than 2:
1.
88. 88. The method of any one of claims 78 to 87, wherein the adsorbent is prepared using at least one cross-linking agent and at least one monomer.
89. 89. The method of claim 88, wherein the monomer is selected from the group consisting of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyl toluene, vinyl naphthalene, vinyl benzyl alcohol, vinyl formamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinyl naphthalene, trivinyl cyclohexane, divinyl sulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane trimeth ... acrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide, and mixtures thereof.
90. 90. The method of claim 88 or 89, wherein the crosslinking agent comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.
91. 91. The method of any one of claims 88 to 90, wherein the adsorbent is additionally prepared with at least one dispersing agent and at least one porogen.
92. 92. The method of any one of claims 78-91, wherein the adsorbent comprises a biocompatible and hemocompatible exterior coating covalently bonded to the adsorbent by free radical graft polymerization.
93. 93. The method of any one of claims 78-92, wherein the adsorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.
94. 94. The method of any one of claims 78-93, wherein the cancer therapy or immunotherapy comprises one or more of radiation therapy, chemotherapy, hypothermia, hyperthermia, checkpoint inhibitors, monoclonal antibodies, bispecific T cell engagers, CAR-T cell immunotherapy, cancer vaccines, and oncolytic viruses.
95. 95. The method of any one of claims 78 to 94, wherein the method improves the efficacy of the cancer treatment.
96. 95. The method of any one of claims 78 to 94, wherein the method improves the efficacy of the immunotherapy.
97. 97. The method of any one of claims 78-96, wherein the adsorbent reduces concentrations of one or more of cytokines, chemokines, inflammatory mediators, toxins, electrolytes, chemicals, cellular debris, and metabolic waste products in the patient compared to an untreated subject.
98. 97. The method of any one of claims 78-96, wherein the method reduces entry of CAR-T cells and other activated cells into the central nervous system compared to an untreated subject.
99. 97. The method of any one of claims 78-96, wherein the method reduces damage from one or more of cytokine release syndrome (CRS), CAR-T cell associated encephalopathy syndrome (CRES), chimeric antigen receptor T cell therapy associated toxicity (CARTOX), immune effector cell associated neurotoxicity (ICANS), or tumor lysis syndrome (TLS) compared to an untreated subject.
100. 97. The method of any one of claims 78-96, wherein the method ameliorates one or more of the onset, severity, or progression of cachexia.
101. The method of any one of claims 78 to 96, wherein administration of the adsorbent removes one or more of: a) cytokines or chemokines, b) soluble checkpoint molecules, and c) extracellular vesicles associated with checkpoint molecules from the subject's bodily fluid.
102. 102. The method of claim 101, wherein the soluble or extracellular vesicle-associated checkpoint molecule is one or more of the examples found in Table 1.
103. 102. The method of claim 101, wherein the cytokine or chemokine comprises one or more members of the interleukin, interferon, tumor growth factor, or tumor necrosis factor family.
